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Terms of Reference 
 
The Department of Transport, Tourism and Sport (DTTAS), on behalf of the Minister, wrote to the 
Medial Bureau of Road Safety (MBRS), in January 2012, stating that the “DTTAS wanted to gain a greater 
knowledge of the present thinking and developments in the area of detection of drug driving”. The 
DTTAS requested that the MBRS ”undertake a considered study on all aspects of roadside drug testing, 
including reference to and analysis of any equipment currently in use or anticipated to be introduced for 
carrying out  such tests and indication of the likely timescale involved in reaching an acceptable solution 
to the problem”.  This report is the response to the DTTAS’ request. 
9 
Summary 
 
This report is a study on all aspects of roadside drug testing, including reference to and analysis of any 
equipment currently in use or anticipated to be used to carry out such tests. The report considers the 
current definition of a “drug” and current drug analysis procedure under the Road Traffic Acts.  As part 
of the evidence base for driving under the influence of drugs (DUID) the prevalence of drug taking in the 
general population, in the driver population, in suspected drugs driving population and the toxicology 
data for drivers in fatal crashes are presented and reviewed. International data and reports are also 
considered to inform the relevant bodies as to drugs that could and should be targeted for testing into 
the future. The studies indicate that cannabis and benzodiazepines are currently the most prevalent 
drugs in driving under the influence of drugs cases followed by the opiates, methadone and cocaine. 
The effects of individual drugs on driving and the relationship between impairment and measurement of 
those drugs in the human body are examined. The methods of detection of DUID by means of roadside 
impairment testing and with particular emphasis on roadside drug testing in oral fluid are reviewed to 
include medical, practical and scientific considerations. The consequential confirmatory laboratory 
testing for drug detection in body fluids including oral fluid in the future is explored.     
Previous international studies and the current status of roadside drug testing in the international 
literature by way of extended studies are presented and support the introduction of roadside chemical 
drug testing devices but also acknowledge certain limitations. The introduction of roadside drug testing 
devices is a far more complex and complicated initiative than was the case for roadside breath alcohol 
testing. 
Four currently available roadside drug testing devices were considered and reviewed to inform this 
report regarding the operation of such devices, their storage and operation conditions,  the scientific 
criteria on which they are based and also the countries which are currently using the devices or propose 
to use them in the near future. 
The practices for DUID roadside testing in 13 other countries were surveyed and are reviewed and 
presented with 8 of these countries or jurisdictions already having in place provision for the use of such 
devices and the remaining 5 countries purposely relying on roadside impairment testing rather than 
devices. 
The report sets out the considerations and options for the introduction of roadside drug testing devices 
in Ireland.  The considerations are under four main headings - legal, operational, scientific and medical.    
A number of options are outlined with the considered recommendation being the combination of 
roadside traffic impairment testing and roadside chemical drug testing. An implementation plan for the 
introduction of the recommended option is set out including a timeframe for implementation of the 
roadside drug testing recommendation, if so approved.   
10 
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Chapter 1: Introduction 
1.1: Introduction 
Driving under the influence of drugs (DUID) has been a statutory offence in Ireland since the Road Traffic 
Act 1961.   The Medical Bureau of Road Safety (MBRS) is the independent forensic body responsible for 
chemical testing of intoxicants under the Road Traffic Acts and also for the approval, supply and testing 
of apparatus for determining the presence or concentration of such intoxicants.    The current statutory 
provisions for intoxicated driving offences are set out in Chapter 2 of the Road Traffic Act 2010.    
Section 4 (1) of the 2010 Act states that “a person shall not drive or attempt to drive a mechanically 
propelled vehicle in a public place while he or she is under the influence of an intoxicant to such an 
extent as to be incapable of having proper control of the vehicle.”  The law sets out specified 
concentrations of alcohol in the blood, urine and breath (per se levels) which if exceeded constitute an 
offence.   Such levels are not set out for drug intoxicants and the current offence requires that there be 
proven impairment or incapacity together with the confirmed presence of the drug or drugs other than 
alcohol.    
With the introduction of the Road Traffic Act 1961, which removed the word “drunk” there was still no 
provision for alcohol limits and there was no standard test for determining the level of incapacity of the 
driver and doctors relied on clinical examination containing some sobriety tests. In 1968 a per se limit for 
alcohol was introduced and the limit was set at 125mg/100ml in blood. Since then with improvements in 
analytical technology and research into road trauma the alcohol limit has been reduced to 50 mg/100ml 
in blood.  
Mandatory alcohol testing at the roadside was also accommodated by the improvements in detection 
technology and a fast and effective method of breath testing is achievable and in use in most 
jurisdictions worldwide, including Ireland.  
However, in the case of drugs and driving, while it is mentioned in the 1961 RTA, roadside detection of 
drugs has not progressed scientifically and technologically to the same extent as with alcohol. The 
detection of drugs is complicated by the fact that generally they are consumed in lower quantities than 
alcohol and are therefore detectable at lower concentrations. This presents an analytical challenge. 
When testing for alcohol it is the only compound that is targeted, drug detection involves testing for 
multiple compounds. Alcohol is a volatile compound and so it can be detected in breath and also can be 
easily liberated from blood and urine for laboratory analysis. This is not the case with drugs and this 
complicates their analysis.  Drug use patterns change over time and so the drugs that should be targeted 
require constant review.  Because it is not possible to detect drugs in breath at present, alternative 
matrices had to be found.  This report will outline some of the major research that has been carried out 
worldwide and also outlines what measures other jurisdictions use in relation to roadside drug testing.  
There is continued research into road trauma and drugs and continued improvements being made in the 
detection technology, however drugs are more problematic due to their diversity and complexity and 
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the solutions being adopted are not as cheap or as quick and simple to operate as roadside alcohol 
testing.   
1.2: Definition of a “Drug” 
The term “intoxicant” is defined in the Road Traffic Act 2010 as including “alcohol and drugs and any 
combination of drugs and alcohol”. However, there is no definition of “drug” in the statute and 
therefore the term is a wide definition to include any substances recognised as drugs, be they controlled 
drugs, prescription drugs and medicines or over the counter drugs and medicines. Road Traffic 
legislation does not distinguish between so called illicit drugs and licit drugs. The consideration of driving 
capacity or safety is the core element rather than the legal status of the drug.     
The relevant legislation relating to licit products for human use in Ireland derives from the EU Directive 
2004/27/EC which considered medicinal products in the context of their presentation and the purpose 
for which they are administered. Article 1 of that Directive defines a medicinal product as “any 
substance or combination of substances presented as having properties treating or preventing disease in 
human beings; or any substance or combination of substances which may be used in or administered to 
human beings either with a view to restoring, correcting or modifying physiological functions by exerting 
a pharmacological, immunological or metabolic action, or to making a medical diagnosis”.  The most 
recent comprehensive statutory instrument dealing with medicinal products was the Statutory 
Instrument 540/2003 Medicinal Products (Prescription and Control of Supply) Regulations 2003.    
Drugs such as cannabis, cocaine and ecstasy fall within the category of controlled or illicit drugs and they 
are subject to the provisions of the Misuse of Drugs Act 1997-1984 (as amended) and the regulations 
made under those parent Acts.  These regulations are updated as required and recent updates occurred 
in a number of Orders in 2010 to deal with the emergence of so called “head shop drugs”. The 
Oireachtas has also enacted the Criminal Justice (Psychoactive Substances) Act 2010. 
1.3: Targeted Outcome of Review 
The problem of drug driving is under detected when compared to the detection of drink driving. Within 
a framework of improved detection and analysis, with particular emphasis on what happens at roadside 
checkpoints this initiative has a clear aim, in the context of the road safety strategy, of improving road 
safety with a decrease in drug related fatalities, road traffic injuries and collisions. 
Similar to the mandatory breath testing program currently in place, the objectives of mandatory drug 
testing would be to:  
 Increase detection of DUID 
 Educate drivers and increase awareness of the dangers of DUID 
 Change driver behaviour by deterring them from DUID 
 Reduce road traffic accidents, injuries and fatalities 
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In considering all aspects of driving under the influence of drugs there are four distinct and overlapping 
areas:  
 The legislative framework will determine what can be done and the effectiveness of 
enforcement.  
 The operational requirements of An Garda Síochána and the MBRS in terms of the practicalities 
of devices including their scientific basis, the training requirements for their use, the testing of 
devices and the cost, which will all impact on the timescale for the introduction of suitable 
devices at the roadside.  
 The scientific requirements for specificity and sensitivity having regard to levels of detection and 
cut-offs. 
 The overlap with the medical aspects of fitness to drive currently being reviewed by the Royal 
College of Physicians of Ireland and the Road Safety Authority which must be integrated with 
the other necessary aspects.    
The MBRS has kept a abreast of developments in oral fluid testing both in the laboratory and at the 
roadside. The MBRS has not yet entered into any scientific or technical evaluation of any devices or 
system of oral fluid testing. The MBRS therefore has not approved any device for the purposes of oral 
fluid testing at the roadside.   
In this review we give consideration to:  
 Prevalence 
 Effects of drugs on driving and relationship between impairment and bodily fluid 
 Detection of driving under the influence of drugs 
 Previous studies and current status of roadside testing 
 Review of selected current roadside chemical testing devices 
 Practice in other countries 
 Considerations and options for roadside drug testing 
 Implementation of the recommended  programme  for roadside drug testing  
 
1.4: Current Drug Detection and Analysis Procedure Under the Road Traffic 
Act 
When a driver is arrested under the Road Traffic Act 2010, on suspicion of driving under the influence of 
an intoxicant an evidential sample of blood, urine or breath is taken.  A driver is arrested on such 
suspicion following observed impaired driving, from which a Garda forms the opinion that the person is 
intoxicated, or arising from a mandatory alcohol testing (MAT) checkpoint following a fail result in the 
roadside breath alcohol test  or observation by a Garda who forms the relevant opinion as to 
intoxication.  There is currently no provision in the law for mandatory intoxicant testing (MIT). There is a 
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provision for road traffic impairment testing (RTIT) which has not been enacted to date (See chapter 4, 
roadside impairment testing). 
When a specimen of blood or urine is forwarded under the Road Traffic Act 2010 to the MBRS, it is 
analysed in the first instance for the concentration of alcohol.  If the blood alcohol concentration is 
80mg/100mL or less or the urine alcohol concentration is 107mg/100mL or less, the specimen is then 
analysed for the presence of seven drugs or classes of drugs by means of a two stage analytical process.  
The Bureau analyses for cannabinoids, benzodiazepine class, amphetamines class, methamphetamine 
class, cocaine, methadone and opiate class drugs.  The Bureau issues a statutory certificate indicating 
the presence of a drug or none detected to the driver and the Gardaí. This certificate along with the 
Garda evidence of impairment is required for prosecution purposes. A Garda can still request drug 
analyses if the alcohol level is greater than the legal limits or if an evidential breath alcohol test has been 
carried out and found to be below the legal limit.  The classes of drug or drugs which the MBRS test for 
are kept under review. Prevalence and trends of drug use are very important factors which require 
consideration in the detection of drugs in drivers. 
15 
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Chapter 2: Prevalence 
2.1: Introduction 
A review of available Irish and International data was conducted in order to establish the prevalence of 
drugs used both in the driving population and the wider population. In terms of Irish data the following 
were considered:  
 The nationwide survey conducted by the MBRS in 2000-2001  
 MBRS Specimen Analysis Data 2007-2011 
 The NACD drug prevalence survey from 2010/2011  
 Fatal Crash Toxicology data from the  National Drug-Related Death Index  (NDRDI) and the 
Kildare County Coroner  
 The RSA ‘Driving Under the Influence of Drugs’ report   
 Garda DUI crime statistics.  
In the case of International prevalence data from the European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA), the DRUID project and the North Report were taken into consideration. The 
objective of this review was to identify the most prevalent drugs, so that this would inform any road side 
testing strategy that may be introduced. 
2.2: Ireland 
2.2.1: Nationwide Survey: Medical Bureau of Road Safety and University College Dublin 2000-2001  
The MBRS was commissioned by the then Department of Environment and Local Government to carry 
out a nationwide survey during 2000 and 2001 on blood and urine specimens from drivers suspected of 
intoxicated driving, in order to determine the trends in DUID in Ireland and to establish an ‘evidence 
based’ model to inform future Road Safety Strategies and a review of the legislation at that time.  2,000 
specimens were selected for drug analysis, 1,000 with results under the limit for alcohol and 1,000 over 
the limit of 80mg/100mL in blood or 107mg/100mL in urine. [1, 2]    
The drugs tested for were: 
 Amphetamine Class 
 Methamphetamine Class 
 Opiate Class 
 Cannabinoids Class 
 Methadone 
 Cocaine 
 Benzodiazepine Class 
231 (33.1%) of the drivers under the legal limit for alcohol tested positive for one or more of the 
relevant drugs, and the corresponding figures for drivers over the limit was 142 (14.2%).   Using 
weighted analysis this corresponded to 15.7% of all tested drivers (15.8% in men and 14.5% in women).   
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Of drivers who had minimal blood alcohol levels (<10mg/100mL), 67.9% were taking at least one type of 
drug. The prevalence of taking drugs reduced steadily as alcohol concentration increased, but still 
remained as high as 11.1% for drivers with blood alcohol concentrations greater than 200mg/100mL.  
Being under the limit for alcohol, being stopped in a city area, being stopped between 6am and 4pm, or 
4pm and 9pm, and being of the younger age group were each independently associated with drug 
positivity. 
This study also showed that the impairing drugs being used by drivers were both licit and illicit in nature. 
The most prevalent drug by far was Cannabis followed by Benzodiazepines.  
2.2.2: Medical Bureau of Road Safety Specimen Analysis Data 2007-2011 
Testing for drugs has continued as part of the enforcement of the Road Traffic Act and drug test results 
for 7,776 specimens of blood and urine tested between the years 2007-2011 were reviewed. Cannabis 
followed by benzodiazepines continued to be the most prevalent drugs detected.  Cocaine, opiates and 
methadone are the next most prevalent and have increased in prevalence when compared with the 
2000-2001 study. Amphetamine and methamphetamine type compounds are less prevalent recently 
than previously reported in that study. The data from the 2000-2001 study and the review of the data 
between 2007 and 2011 have been tabulated (See Table 2.1) and charted (Figure 2.1). The total number 
of specimens analysed and the number subsequently certified for the presence of a drug or drugs is set 
out for 2007-2011 (Table 2.2). 
 
Drug Class Prevalence (% of all Under the Alcohol Limit Tested Drivers 
Positive for drugs) 
 2000/1 2007 2008 2009 2010 2011 
Cannabis 63.1 54.3 63.1 57.7 48.9 52.2 
Amphetamines (Incl. MDA) 25.4 11.9 4.7 2.6 5.2 5.3 
Methamphetamines (Incl. MDMA) 27.2 13.0 8.2 1.5 3.3 3.7 
Opiates 20.8 39.1 33.7 12.4 24.9 15.9 
Cocaine 8.5 17.2 15.9 23.8 9.5 10.2 
Methadone 7.5 17.8 15.9 8.8 10.8 7.2 
Benzodiazepines 27.1 45.5 44.4 44.2 46.7 40.5 
Table 2.1: Prevalence for the 7 classes of drugs tested for by the MBRS from the study conducted in 2000-2001 and also for the 
years 2007-2011. 
 
 2007 2008 2009 2010 2011 
Total Number of Specimens Analysed 1,154 1,867 1,980 1,554 1,221 
Total Number of Specimens Certified 952 1,411 1,444 1,163 865 
Table 2.2: The total number of specimens analysed and the number subsequently certified for the confirmed presence of a drug 
or drugs for the years 2007-2011. 
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Figure 2.1: Prevalence for the 7 classes of drugs tested for by the MBRS from the study conducted in 2000-2001 and also for the 
years 2007-2011. 
Figure 2.2 below gives a percentage breakdown of the number of classes of drug that specimens tested 
are found to contain for the years 2008-2011. This shows that poly-drug use, as reported in 2000-2001 
study, is still being observed to the end of 2011 [1]. As can be seen 23.5% are positive for no drugs and 
30.7% are positive for one drug. The remaining 45.8% are positive for two or more drugs.  
 
Figure 2.2: Percentage breakdown of the number of classes of drug, that specimens tested, are found to contain between 2008 
and 2011 
19 
 
2.2.3: National Advisory Committee on Drugs: Drug Prevalence Survey 2010/2011 
Data published by the National Advisory Committee on Drugs (NACD) on surveys of drugs trends is 
available. In 2012 the NACD and the Public Health Information and Research Branch (PHIRB) in Northern 
Ireland published data from a household survey conducted in 2010/2011 [3]. The results of the survey 
showed that cannabis was the most commonly used illegal drug with a lifetime prevalence of 25% in the 
Republic of Ireland and 24% in Northern Ireland. Cannabis use was more prevalent in the younger age 
groups.  Another finding was that women and older adults continue to report higher levels of use of 
sedatives, tranquiliser and anti-depressants. This shows that in terms of the use of cannabis and 
benzodiazepines the most up to date data points to the fact the cannabis and drugs such as 
benzodiazepines are the most relevant in the driving population as was borne out in the MBRS survey in 
2000/2001 and MBRS data from 2007-2011. 
It is important to address the numerous new psychoactive substances which have been available on the 
Irish market in the last number of years. From the study conducted by the Dublin Institute of Technology 
(DIT) it would appear that there are a significant number of different drugs sold as intoxicating 
alternatives to illegal drugs [4]. Examples are drugs such as benzylpiperizine and mephedrone. These 
substances have received a significant deal of media attention in the last few years.  These drugs are 
sold over the internet and through ‘Head Shops’. The difficulty with these is that suppliers offer drugs 
for sale which are not currently controlled by any relevant legislation. If the drug is considered to be a 
danger to public health and are subsequently brought under control an alternative is very rapidly 
available. This presents a new challenge for policymakers, legislators and scientists. A new consideration 
in the NACD/PHIRB  2010/2011 survey was that new psychoactive drugs were included [3]. It showed 
that last year prevalence was 9.7% in the 15-24 year age group and 4.6% in the 25-34 year age group 
highlighting the significance of this new trend.  The MBRS does not currently test for these new 
psychoactive substances, however the classes of drugs for testing is under continual review. 
2.2.4: Fatal Crash Toxicology Data – National and County Kildare Studies 
The National Drug-Related Death Index (NDRDI) was established in September 2005 to comply with 
Action 67 of the 2001–2008 National Drugs Strategy. [5] 
Road Traffic Collisions (RTC) deaths in vehicle drivers with a positive toxicology for an illicit drug(s), 
recorded by the NDRDI 2004 to 2009 in Coroner’s Districts Nationally 
A review was undertaken by the NDRDI of drug toxicology from Coroners’ nationwide data on driver 
fatalities between 2001 and 2009. The following analysis presents the NDRDI data on road traffic 
collisions (RTC) deaths among vehicle drivers in Ireland, for the period 2004 to 2009, where the 
individual had a positive toxicology finding for an illicit drug(s) at the time of death.  In this six year 
period there were 93 of these deaths recorded by the NDRDI.  Cannabis (38.7%) was the most common 
illicit drug found in the toxicology of these 93 individuals, followed by cocaine (23.7%) and MDMA 
(18.3%) (Figure 2.3).  A more in-depth description of the NDRDI methodology is set out on pages 6-8 of 
the HRB Trend Series 8. [6]  
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Figure 2.3    Positive toxicology for an illicit drug(s), vehicle drivers, NDRDI 2004-2009 n=93 
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RTC deaths in drivers of a vehicle (car, van or motorcycle) reported to the Coroner’s District of Kildare 
1998 to 2009 
A review of road traffic collisions and drug and alcohol toxicology analyses from the Coroners District in 
Kildare during the period of 1998 – 2009 was also carried out. This was undertaken jointly by the NDRDI 
and the Kildare Coroner.  The focus of the analysis was on deaths where a positive toxicology finding 
was recorded.   In the eleven year period a total of 164 deaths due to road traffic collisions were 
reported in the district of Kildare. The majority of the deaths were males (81.7%) and between the ages 
of 15-34 years (61%).   The median age was 29.5 years.    
 
Of the 164 deaths during the reporting period 1998 to 2009, 92 (56.1%) were the driver of a vehicle (car, 
van or motorcycle).  Of these 92 deaths, 46 (50%) had a recorded positive toxicology. Of the 92 driver 
deaths: 
 
 31 (33.7%) had a positive toxicology for BAC ≥80mg/100mls.  
 6 (6.5%) had a positive toxicology for a BAC≥80mg/100mls and a drug(s). 
 9 (9.8%) had a positive toxicology for a drug(s). 
 A further 6 drivers (6.5%) had a positive toxicology for BAC ≥20mg/100mls. 
 
These data are set out in Table 2.3 and charted in Figure 2.4.  
 
Year ‘98 ‘99 ‘00 ‘01 ‘02 ‘03 ‘04 ‘05 ‘06 ‘07 ‘08 ‘09 
Total deaths BAC≥80mg/100mls and/or drugs 1 3 6 7 4 5 3 2 7 1 3 4 
Alcohol only 1 3 4 7 3 4 0 1 4 0 1 3 
Alcohol and drug(s) 0 0 1 0 0 0 1 1 1 0 1 1 
Drug(s) only 0 0 1 0 1 1 2 0 2 1 1 0 
Table 2.3    RTC deaths among vehicle drivers, reported to the Coroner’s District of Kildare, BAC≥80mg/100mls and/or drug(s), 
1998 to 2009,  n=46 
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* This is a multiresponse graph taking into account individual incidences of alcohol and drugs present on the toxicology report.  Therefore, totals exceed the 46 deaths. 
Figure 2.4    RTC deaths among vehicle drivers, repo rted to the Coroner’s District of Kildare, alcohol or drug(s) present in toxicology, 1998 to 2009 n=46 
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2.2.5: Road Safety Authority DUID Report 2010 
The RSA published a report in 2010 entitled ‘Driving Under the Influence of Drugs: A review of the 
Evidence and Legislation’ [7]. This report reviewed DUID in the context of: 
 Prevalence 
 Characteristics and perception of risks of DUID drivers 
 DUID legislation and policy and procedures 
 Detection of drugs in drivers 
The report also made a number of recommendations and concluded that: 
 DUID is significant problem worldwide 
 There was a general lack of knowledge around the effects of drugs on driving 
 The main drugs of concern were cannabis and benzodiazepines and also drugs in combination 
with alcohol. 
Chapter 5 of the report dealt specifically with the detection of drugs in drivers. From an enforcement 
and legislative perspective the report concluded per se DUID laws can assist in the prosecution of DUID. 
2.2.6: Garda DUI Recorded Crime Statistics 2004-2011 
The incidence of Garda recorded crime statistics 2004-2011 [8] for driving or being in charge of a vehicle 
while over the alcohol limit or under the influence of a drug  are reproduced below (Table 2.4). 
Year ‘04 ‘05 ‘06 ‘07 ‘08 ‘09 ‘10 ‘11 
Driving/In charge of a vehicle while 
over legal alcohol limit 
12,168 14,075 18,598 19,822 17,940 13,771 10,682 9,013 
Driving/In charge of a vehicle while 
under the influence of a drug 
77 106 117 270 728 891 602 421 
Table 2.4: Recorded Crime Offences (Number) for Driving/In charge of a vehicle while over legal alcohol limit and Driving/In 
charge of a vehicle while under the influence of drug 2004-2011 
There has been a decrease in the number of DUID incidents detected by An Garda Síochána since 2009 
and there has always been a difference between the number of samples submitted to the MBRS which 
on analysis were found to be confirmed positive for drugs other than alcohol (Table 2.2) and the 
corresponding numbers recorded in crime statistics (Table 2.4) and subsequently prosecuted in the 
courts for DUID. These differences have never been satisfactorily explained but may be due to legal 
difficulties encountered in evidential proofs of impaired driving whilst under the influence of drugs other 
than alcohol.    
2.3: International 
2.3.1: European Monitoring Centre for Drugs and Drug Addiction 2011 
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) provide data in a European 
context.  The EMCDDA reported in its 2011 annual report that the last year prevalence for cannabis in 
15-64 year olds was 6.7% and the last month prevalence for cannabis in the same group was 3.6% [9]. In 
the 15-34 year old age group the last year prevalence for Cannabis was 12% and the last month 
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prevalence for cannabis was 6.6%. The youngest age group was the 15-24 year old age group which 
showed the highest prevalence with last year prevalence for cannabis being 15.2% and the last month 
prevalence for Cannabis being 8.0%. When compared with prevalence data from Canada and the U.S.A. 
last year prevalence for Cannabis was 21.6% and 24.1% respectively in the young adult age group (ca. 
15-34 years) [9]. The EMCDDA reports that last year prevalence for amphetamine and ecstasy is ca. 0.5% 
in the 15-64 age group and ca. 1-2% in the 15-34 age group.  Last year cocaine prevalence in Europe is 
1.2% in the 15-64 age group and 2.1 in the 15-34 age groups. Again as with cannabis prevalence the 
European averages are lower than Northern America.  While the EMCDDA do not provide details of 
opioids prevalence it does take into consideration opioids other than the most common methadone, 
morphine and codeine and cites emerging trends in the misuse of opioids such as fentanyl, oxycodone,  
hydrocodone and buprenorphine. 
The 2011 EMCDDA annual report highlighted the problem presented by new psychoactive substances 
[9]. Between the establishment of the EMCDDA in 1997 and 2010 the EMCDDA has included 150 drugs 
into its monitoring programme, 65 of these were added in 2009 and 2010. A further 70 were added in 
2012. This clearly demonstrates that the illicit drug problem is ‘increasingly dynamic and fast moving in 
nature’ as suggested in the report. 
2.3.2: DRUID (Driving Under the Influence of Drugs) 2006 - 2011 
Various studies have been carried out worldwide, at European level and in Ireland to ascertain the 
prevalence of drugs driving.  However, prevalence data from different countries have not been readily 
comparable owing to differences in study designs. One of the most significant projects to conduct 
research into drugs, alcohol and medicines in the context of EU Transport Policy and Road Safety was 
the DRUID (Driving Under the Influence of Drugs) project which was funded by the European Union.  The 
research consortium participants were 37 institutions from 19 countries. DRUID’s scientific structure 
consisted of 7 different “work packages” on:  
 Methodology and Research (observational, experimental, accident databases);  
 Epidemiology (prevalence and risks of psychoactive substances in driving);  
 Enforcement (on site detection of impairing substances);  
 Classification and Categorisation (of medicines in driving);  
 Rehabilitation (behavioural change programmes);  
 Withdrawal (of driving licence); 
 Dissemination (information campaigns for general public and healthcare professionals) 
The project commenced in 2006 and the final conference took place in September 2011 at which the 
outcome of the completed research was presented [10].   The epidemiology (with methodology and 
research) of drug and alcohol consumption in the driving population, in drivers killed or injured in 
crashes and in drivers involved in fatal crashes was presented.    The participating countries, in which 
these studies were conducted in, show prevalence in the general driving population of up to 10% for 
alcohol; up to 2% for drugs in combination with alcohol; up to 5% for illicit drugs; and up to 3% for 
medicines.  There were limitations on some of the countries studies, e.g. small sample size for some of 
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the studies involving injured drivers.  The findings of the DRUID project with respect to roadside 
chemical testing are discussed in chapter 5. 
2.3.4: UK: The North Report 2010 
The North Report, published in 2010, was a ‘Review of Evidence Related to Drug Driving in the UK’ which 
was overseen by Sir Peter North and his team for the UK Government [11]. The first part of this report 
dealt with prevalence and it noted that there was a lack of recent UK data on the impact of drug driving 
on casualty rates. The review recommended the use of Coroner data and data from toxicology 
laboratories as potential sources of data and acknowledged that this would require co-ordination among 
the stakeholders if it was to be realised as a potential source of data. Analysis of the available data 
sources found that cannabis was the most prevalent drug across all surveys and data sources, but that 
since the mid 1990s there had been an increase in cocaine use in the general population, the DUID 
population and other road users. It cited regional variations such as in Scotland where benzodiazepines 
were the most prevalent, with more that 80% of DUID cases being down to this drug class. In addition 
the review stated that there has been a considerable increase in polydrug use. As the review was 
published in 2010 it refers to anecdotal evidence of a ‘surge in legal highs’.  
 
2.4: Drugs that should be Targeted for Testing: Current and Future 
Taking into consideration the prevalence evidence discussed above it is clear that cannabis and 
benzodiazepines are the most prevalent drugs used both nationally and internationally. It is also clear 
that the pattern of drugs which are used or abused changes. The importance of monitoring these 
changing trends cannot be understated.  Sometimes these changes are short-lived and at other times 
they are more permanent changes. Some considerations leading from this are: 
 The authorised and legal medicinal use of cannabinoids (e.g. Sativex®) is permitted in other 
countries within the EU. In the event that cannabinoids become legally available in the Republic 
of Ireland for medicinal use, this would need to be considered in the framing of any legislation.  
 New prescription medications which have new drug components which cause impairment need 
to be monitored and included in drug testing strategies. Examples of these would be the 
introduction of new opioid drugs such as buprenorphine in the last number of years. 
 There are many drugs which are not currently targeted by the MBRS and these include anti-
histamines, antipsychotics and antidepressants all of which can have impairing effects. Analysis 
of these drugs will form part of the continuing development of the drug testing programme at 
the MBRS. 
 New psychoactive substances legislation describes psychoactive substance as a substance that is 
‘not specifically controlled under existing legislation, that have the capacity to stimulate or 
depress the central nervous system resulting in hallucinations, dependence or significant 
changes to motor function, thinking or behaviour’. The risk is that while a substance may fit the 
description above an absence of evidence in the literature may undermine their categorisation 
as an intoxicant. Careful consideration will need to be given to this issue in road traffic 
legislation. 
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2.5: Conclusion 
Based on the drug testing conducted by the MBRS, national and international drug testing trends, the 
cannabinoids and the benzodiazepines are the most prevalent drugs used, followed to a lesser extent by 
the opiates, methadone and cocaine.  The amphetamine and methamphetamine class drugs are least 
prevalent.  These trends and the emergence of new drugs need to be considered when selecting drug 
targets for roadside drug testing. 
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Chapter 3: The Effects of Drugs and Driving and the Relationship 
Between Impairment and Body Fluids 
3.1: Introduction 
The purpose of this chapter is to provide background on the effects that different drugs have on driving 
and the relationship between impairment and a measured drug level in specific biological specimen 
types is discussed. 
3.2: Drugs and their Effects by Class 
There are many useful resources which deal with the effects of drugs and driving and some of these are 
referenced here [12, 13].  
3.2.1: Cannabinoids 
The chemical compounds unique to the cannabis plant are known as the cannabinoids. The main 
pharmacologically active constituent of cannabis is Δ9-tetrahydrocannabinol (THC). This is a central 
nervous system depressant that may cause ataxia, confusion, dizziness, somnolence, euphoria, 
hallucinations, speech difficulties, weakness, malaise and vision difficulties. Single doses of THC, via 
smoking or oral ingestion, are capable of producing significant psychomotor performance decrements in 
healthy volunteers for up to 24 hours in laboratory studies and up to 3 hours under actual driving 
conditions. The deleterious effects of THC appear to be additive to or possibly synergistic with those of 
alcohol, and the combination of the two agents results in the prolongation as well as enhancement of 
their effects [12, 13].  
3.2.2: Benzodiazepines 
Examples of benzodiazepines are drugs such as diazepam and alprazolam. Many benzodiazepines are 
available on prescription. Such drugs are central nervous system depressants that may cause 
drowsiness, lethargy, dizziness and confusion. Manufacturers state that patients taking these drugs 
should be warned against engaging in potentially hazardous activities requiring mental alertness and 
that they should be advised against the simultaneous use of alcohol and other central nervous system 
(CNS) depressants. Simulator and driving studies have shown that such drugs produce significant driving 
impairment. Single doses of diazepam can increase lateral deviation of lane control, reduce reaction 
times, reduce ability to perform multiple tasks, decrease attention, adversely affect memory and 
cognition and increase the effects of fatigue. Significant impairment is further increased if diazepam is 
combined with low concentrations of alcohol [12, 13].  
3.2.3: Opiates 
Drugs in the opiates class include morphine, codeine and heroin. Many opiates are available on 
prescription. These drugs are central nervous system depressants that can cause drowsiness and 
dizziness, lethargy, ataxia, visual disturbances, weakness and confusion. Some of the drugs are used 
medicinally and manufacturers warn that the drug can impair mental and/or physical abilities required 
for the performance of potentially hazardous tasks and additive depressant effects may be produced by 
the concomitant administration of other CNS depressants, including alcohol. Single or repeated 
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intravenous intramuscular or oral morphine doses given to healthy volunteers as well as former opiate 
addicts, have been shown to be capable of causing subjective sedation and significant psychomotor 
impairment for up to 4 hours after a single dose and for up to 36 hours after a repeated doses in 
laboratory studies [12, 13].  
3.2.4: Methadone 
Methadone is a central nervous system depressant that can cause drowsiness, dizziness, weakness, 
disorientation, lightheadedness and visual disturbances. Prescription users are advised that methadone 
may impair their mental and/or physical abilities required for the performance of potentially hazardous 
tasks, and that the sedative effects of the drug may be enhanced by the concurrent use of other CNS 
depressants such as alcohol. In healthy, non-methadone using volunteers, single doses of methadone 
will impair driving ability [12, 13]. Studies of long-term methadone maintenance patients have shown 
appropriately administered methadone doses do not cause significant psychomotor or cognitive 
impairment when administered regularly and when the subject abstains from all other drugs [14]. 
3.2.5: Cocaine 
Cocaine is a central nervous system stimulant that may cause restlessness, euphoria, dizziness, 
dyskinesia, tremors, dysphoria and insomnia. Chronic usage may lead to personality changes, irritability, 
hyperactivity and psychosis. Observed signs of impairment and driving performance have included 
subjects speeding, losing control of the vehicle, causing collisions, turning in front of other vehicles, high 
risk behavior, inattentive driving and poor impulse control. As the effects of cocaine wear off subjects 
may suffer from fatigue and depression, sleepiness and inattention [12, 13]. 
3.2.6: Amphetamines, Methamphetamines and Ecstasy (MDMA) 
Amphetamine and methamphetamine are central nervous system stimulants that may cause 
restlessness, euphoria, dizziness, dyskinesia, tremor, dysphoria and insomnia. Chronic use may lead to 
personality changes, irritability, hyperactivity and psychosis.  Driving and driving behaviours included; 
speeding, erratic driving and accidents. Other notable effects included nervousness, rapid and non-stop 
speech, un-intelligible speech, disorientation, agitation, staggering and awkward movements, irrational 
violent behavior and unconsciousness.  Impairment is attributed to distraction, disorientation, over 
excitation, hyperactive reflexes, general cognitive impairment or withdrawal, fatigue and 
hypersomnolence [12, 13]. 
MDMA (ecstasy) is a weak central nervous system stimulant that may cause the sensory disturbances, 
nausea and dizziness, ataxia, muscular rigidity, diaphoresis, restlessness and tremor. In driving studies 
moderate effects on vehicle control, acceptance of higher levels of risk, acute changes in cognitive 
performance and impaired information-processing ability were observed [12, 13].  
3.2.7: Prescribed Drugs 
The accident risk is considered to be less for the therapeutic use of drugs because of tolerance 
development and the beneficial effect of treatment, than the risk associated with intermittent, illegal 
use or use outside of professional therapeutic advices. However with certain prescribed drugs used in 
certain situations impairment can occur and can contribute to accident risk [15]. A recent study 
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suggested that particular attention should be given to older drivers (45+) using two or more CNS-acting 
agents [16]. 
3.3: Impairment and Body Fluids 
The two specimen matrices which have been most used in drug driving research and enforcement 
practice to date are blood and urine. Blood collection is the most invasive specimen collection 
procedure and requires transportation of the subject to a Garda station or hospital where a medical 
practitioner or nurse is required to obtain a specimen. In the collection of blood, valuable time is lost 
transiting the suspect and it is inevitable that the level of any impairing drug will decrease from the 
bloodstream during this period.  
Blood gives the most information about the subjects state of intoxication because it correlates relatively 
well with impairment.  The main challenge of identifying specific blood concentrations of drugs, other 
than alcohol, that correlate with specific levels of impairment is compounded by many factors such as:  
 Inter-individual differences (metabolism and tolerance);  
 Polypharmacy and drug interactions;   
 Passage of time between driving and collection of a blood sample.  
For this reason few countries have adopted the per se approach to DUID and many have instead 
adopted a zero tolerance approach for illegal drugs and/or an impairment approach with confirmed 
drug presence for medically prescribed drugs. 
Urine is equally difficult to collect at the roadside. However, urine drug concentrations are not effective 
in establishing impairment, but can be used to establish previous use of a drug.  
The relationship between the level of a drug in oral fluid and impairment has not yet been fully 
established. Some jurisdictions use oral fluid testing with cut-off concentration levels for oral fluid which 
are set administratively. These levels are not based on a relationship to impairment or on any 
correlation between oral fluid and blood levels. 
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Chapter 4: Detection of Driving Under the Influence of Drugs 
4.1: Introduction 
Currently detection of driving whilst under the influence of intoxicants, including drugs other than 
alcohol, is by means of observation of impaired driving or a combination of preliminary alcohol 
breathalyser testing and observation at mandatory alcohol testing (MAT) checkpoints. This chapter deals 
with the two main approaches, which are being adopted internationally, for detection of DUID. These 
two approaches are Roadside Impairment Testing and Roadside Chemical Testing.   
4.2: Roadside Impairment Testing 
In accordance with the Road Safety Strategy 2007 – 2012, the MBRS in partnership with the School of 
Medicine and Medical Science at University College Dublin and An Garda Síochána established a training 
programme for Garda Trainers in Road Traffic Impairment Testing (RTIT), also known as Field 
Impairment Testing or FIT. This was done in the context of the new Section 11 of the Road Traffic Act 
2010 which provided for preliminary impairment testing. Some 80 Garda Trainers were trained and 
certified in a professional course as being proficient in Road Traffic Impairment Testing and are currently 
undertaking training of Garda members to carry out these tests at the roadside. More than 3,000 Garda 
members had been trained up to end of March 2012. The RTIT tests comprise of examination of the 
driver’s pupil; a modified Romberg balance test (an indicator of the drivers ability to balance and 
internal clock); a walk and turn test (assessing walking, balancing and following of instructions); one leg 
stand (balance and counting out loud); and finger to nose test (test of balance and depth perception).   
The proscribed format in which the results are recorded by the Garda carrying out the tests is currently 
being reviewed in terms of possible legislative amendment and is anticipated to be included in road 
traffic legislation for 2012.    
4.3: Roadside Chemical Testing 
4.3.1: Specimen Types 
There are three main specimens types that have been used in testing for drugs in drivers, namely blood 
(or a blood derived product such plasma or serum), urine and oral fluid. Each has advantages and 
disadvantages in the context of roadside testing and these are set out in the Table 4.1. Oral fluid is the 
specimen of choice for roadside drug tests and this is borne out in a survey conducted by the MBRS and 
also in the available literature [10, 17-19]. A key advantage of oral fluid is that it can be collected at the 
roadside and a preliminary chemical test can be conducted at the roadside. For these reasons oral fluid 
testing is the focus of this review. 
4.3.2: Oral Fluid 
Saliva is the secretion product of the saliva glands of the head and mouth. Human saliva glands produce 
between 0.5 and 1.5L of saliva daily. Saliva itself is composed of 99% water, 0.3% protein (mostly 
amylase) and 0.3% mucins. The term saliva is specific to the secretions which originate directly from the 
saliva glands. The fluids found in the oral cavity are a mixture of, predominantly saliva with smaller 
amounts of gingival crevicular fluid, cellular debris and blood. Oral fluid is the term used to describe the 
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fluid collected by placing absorbent pads in the oral fluid cavity or by expectoration (spitting) [20]. Oral 
fluid is predominately saliva. A full review of the anatomy and physiology of saliva is available in Clarke 
[20]. 
Parameter Blood Urine Oral Fluid 
Specimen collection Impractical to collect at the 
roadside. Requires a Doctor or 
Forensic Nurse to collect in a 
Garda Station or Hospital. 
Impractical to collect at the 
roadside. Requires a Doctor or 
Forensic Nurse to collect in a 
Garda Station or Hospital. 
Can be collected non-invasively 
at the roadside by a trained 
law enforcement officer.  
Collection time Depends on the availability of a 
Doctor or Forensic Nurse. 
Legally must be collected 
within 3 hrs. 
Depends on the availability of a 
Doctor or Forensic Nurse. 
Depends on ability of arrestee 
to provide a specimen. Legally 
must be collected within 3 hrs. 
Could require an observed nil 
by mouth period at the 
roadside or station. Specimen 
can take up to 10 minutes to 
collect after this time. 
Sample Integrity Not easily adulterated Not easily adulterated if 
collection is observed.  
Not easily adulterated if 
collection is observed 
Suitability in 
determining the 
presence of a drug 
or drugs 
Suitable Suitable Suitable  
Relationship 
between 
concentration and 
impairment 
Relationship exists but requires 
careful  and qualified 
interpretation by a Toxicologist 
No reliable relationship as drug 
concentration in urine is 
subject to variation. 
Evidence gathered to date that 
some relationship does exist 
however the evidence is still 
incomplete.  
Table 4.1: Differences between blood, urine and oral fluid for a number of important parameters relating to roadside drug 
testing. 
4.3.3: How Drugs Get Into Oral Fluid; Factors Effecting Drug Concentration and Oral Fluid Production  
For drugs to enter the mouth via saliva, the drug molecules must be lipid (fat) soluble, non-ionised and 
unbound to proteins. For this reason, the concentrations of drugs in saliva represent their free non-
ionised portion in the blood plasma [20].  
The pH of saliva can have a significant effect on the level of drug found in saliva compared to the level of 
drug found in the blood at the same time. It has been demonstrated that saliva pH changes as the flow 
rate of saliva changes. It is possible to stimulate saliva production using citrate salts and an example of 
this is where an oral fluid collection device incorporates citrate salts in the absorbent pad. When the pad 
is placed into the mouth, oral fluid production increases due to the effect of the salts. At faster saliva 
flow rates the pH rises, so stimulated saliva would have higher pH and can be as high as pH 8. 
Unstimulated saliva has a low pH between pH 6 and 7 and is fairly constant.  A good example of how the 
change in pH can affect the concentration of the drug found in saliva is for Cocaine, as the saliva pH 
changes from 5 to 7.8, the saliva to plasma ratio for Cocaine varies from 273 to 0.44. So at higher pH 
values there will be very little cocaine while at the lower pH values there will much greater levels of 
Cocaine. As this example shows that there is a poor relationship between oral fluid drug concentrations 
and blood drug concentrations for cocaine due to variations in saliva pH and this effect has to be 
considered for all drug targets [20].  
Spiehler et al. have published the theoretical ranges of saliva to plasma ratios, ranging in pH from 6.4 to 
7.6 for a number of drugs [21]. Due to the saliva to plasma ratio of basic drugs (drugs that are ionised at 
pH values greater than 7) such as opiates, amphetamines and cocaine drug concentrations in oral fluid 
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are easily measurable. In contrast the saliva to plasma ratio of benzodiazepines and cannabis are 
generally low [22]. 
Saliva production is controlled by the CNS. Because drugs also affect the CNS they can interfere with the 
production of saliva. This has implications for the ability to provide oral fluid specimens based on the 
drug the driver may be using. Drugs which effect the secretion of oral fluid include amphetamine and 
MDMA where typically oral fluid production is reduced. This can also be the case with cannabis, sedating 
antihistamines, antipsychotic drugs, ant-cholinergic drugs and a number of antidepressants [17].  
In addition to the introduction of drugs via the saliva glands, it is also possible that drugs are present in 
the mouth due to smoking, oral consumption and snorting [23]. Because of this drugs may be detectable 
in the mouth due to direct contact and/or recent consumption.  
4.3.4: Specimen Collection for Roadside Chemical Testing 
Expectoration or spitting provides a neat oral fluid, but this is a very viscous fluid and it can be difficult 
to work with at the roadside. In addition it can be contaminated with food and other debris from the 
mouth such as cellular matter. Commercial oral fluid collection devices are available which get around 
the sample handling difficulties associated with the collection of a neat sample. These typically take the 
form of an absorbent material made from cotton or polyester, which is used to collect oral fluid. The pad 
can then be added to a diluent and the resultant fluid is used for testing. Other devices involve 
squeezing absorbed oral fluid from a foam pad onto the drug detection device. Collection times vary, 
however, they can be as short as a couple of seconds, and as long as 10 minutes. Collection volumes also 
vary where some devices collect only enough for the roadside test and others which collect sufficient for 
roadside testing and laboratory testing. 
4.3.5: Onsite Oral Fluid Tests 
There are numerous on-site testing systems for drugs in oral fluid. These tests can be described as 
immunochromatographic devices. They generally operate by lateral diffusion of the oral fluid sample 
mixed with labeled antibodies in a buffer across lines of immobilised drugs. The specimen is collected 
from the mouth of the donor and applied to the test strip. Figure 4.1 depicts an example which involves 
a specimen containing morphine. At the start end of the strip, where the sample is applied, a buffer 
containing antibodies for the drug is added.  When drugs are present in the oral fluid, they bind to the 
antibodies in the buffer and travel down the strip. When drugs are absent the antibodies travel down 
the strip and are free to bind with the immobilised drug (hapten-protein conjugate) in the test region at 
the end of the strip. When drugs are present they will be bound to the antibodies in the buffer and pass 
by this immobilised drug (hapten-protein conjugate) in the test line. The operator can see the result 
because the antibodies are labeled with colloidal gold and will be visible as a red line, indicating that no 
drug was present. Figure 4.2 depicts the four possible outcomes of such a test for a single analyte. The 
test normally includes a control the purpose of which is to ensure that the test has worked correctly. If 
the control is not visible the test is invalid.  The tests are single use only. This is the same type of 
technology that is used in point of care urine tests used in workplace drug testing and pregnancy testing.  
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Figure 4.1: Diagram of an oral fluid test for opiates. The diagram shows the test strip in the upper left. The strip would normally 
be housed in the plastic cartridge shown on the lower right. The cartridge include the sample well and the test window. 
Reproduced from reference [24] 
 
 
Figure 4.2: The four possible outcomes of a single analyte immunochromatographic test where C is the control line and T is the 
test line. Reproduced from reference [25] 
It is worth noting that there can be a degree of subjectivity in interpreting positives and negatives. 
Figure 4.3 shows a specimen which has been tested for cannabis and was found to be negative using a 
test for oral fluid with a cut-off for THC at 25ng/ml (see section 4.4.1 for an explanation of cut-offs). As 
can be seen there is a visible line in the test region indicating that the specimen is negative. Figure 4.4 
shows a specimen which has been tested in the same way and is positive. Figure 4.5 shows cannabis 
specimen which has been tested in the same way which contained 6ng/ml of THC. This specimen is 
negative however a faint line is visible. For this reason many of the manufacturers have developed 
electronic readers which use cameras to detect the lines and provide a more consistent interpretation of 
the result. These also have the benefit of being able to export data to a printer or other electronic 
media.  
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Figure 4.3: An oral fluid specimen tested for cannabis and found to be negative due to the strong test line on the left and strong 
control line on the right. Reproduced from reference [26] 
 
Figure 4.4: An oral fluid specimen tested for cannabis and found to be positive due to the absence of a test line on the left and 
strong control line on the right. Reproduced from reference [26] 
 
Figure 4.5: An oral fluid specimen tested for cannabis and found to be negative due to the weak test line on the left and strong 
control line on the right. Reproduced from reference [26] 
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4.3.6: Adulteration 
The possibility of adulteration in the case of roadside collection would need to be considered in the 
selection of a device. Adulterants could be added to the mouth before a specimen is taken which could 
interfere with the ability of the test to give a reliable result. For this reason, a period of time should be 
allowed to elapse before a specimen is taken under supervision. Proper training and conduct of 
specimen collection should rule out the possibility of adulteration. 
4.3.7: Interfering Substances 
A British “Guide to Type” for preliminary drug testing recommended a number of potential interfering 
substances (and concentrations) that should be tested for when evaluating oral fluid testing devices, 
including cigarette smoke (unspecified volume), sodium bicarbonate (50 ng/ml), caffeine (50 ng/ml), 
menthol (50 ng/ml), vitamins C (50 ng/ml) and phenylalanine (50 ng/ml) [27].  Any other potential 
intereferents should also be considered. 
4.3.8: Contamination 
It has been reported that oral fluid testing devices and oral fluid collecting devices, which are not 
properly used can in themselves become contaminated with airborne drug from cannabis smoke [28]. 
Training of the Gardaí in the proper use of the oral fluid collection devices will avoid the possibility of 
airborne or surface contamination. 
4.3.9: Environmental Considerations 
The lighting conditions may have an impact on devices which are visually read or interpreted. Devices 
with readers would get around this if they were equipped with screens capable of reading in low light 
(e.g. backlit screens). All of the devices use liquid as part of the development of the test and so the 
operation of devices could be affected by cold weather (freezing) and also by hot weather 
(evaporation/humidity). Manufacturers normally advise on an optimum working temperature and 
humidity ranges for devices.   
4.3.10: Health Risks Associated with Handling Oral Fluid Specimens. 
Saliva is known to be a source of infectious microorganisms therefore, appropriate precautions need to 
be taken. Devices should be disposed of in accordance with proper waste disposal guidelines (e.g. Garda 
Health and Safety procedures). 
4.4: Important Concepts for Evaluation of Roadside Chemical Testing Devices 
4.4.1: Drug Cut-offs 
In drug testing generally cut-off concentrations are applied. This means that when the drug level is 
below the cut-off concentration the result is negative and where the result is at or above the cut-off 
concentration the result is positive.  Cut-offs are often set so that detection is possible within a 
reasonable timeframe, but that the window of detection does not persist for too long a period after 
abstinence from the drug under test.  In oral fluid, drug cut-offs have been proposed by various 
institutions, projects and countries. The oral fluid cut-offs tend to be lower for drugs than the commonly 
applied screening cut-offs for DUID in urine and blood [29]. In addition it is not uncommon for the cut-
offs for onsite testing and laboratory testing to be different. In some cases this is because the onsite test 
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is a broad spectrum test for a class of drugs, e.g. opiates, whereas the laboratory test is capable of 
detecting and quantifying the individual members of the opiate drug class, e.g. morphine, codeine.  
4.4.2: Cross Reactivity 
All of the available roadside tests are based on lateral flow immunoassay principles. The way 
immunoassay testing works is that an antibody is produced that has a high degree of binding to the 
chemical that is to be tested for and this is incorporated into the test device. This binding is based on the 
shape of the chemical and the impression in the antibody matching much like a key (drug) in a lock 
(antibody). Whilst this binding is highly specific it is always possible that other chemicals or parts of 
chemicals could also fit the impression in the antibody. For structurally related compounds in a class this 
is advantageous, as for example an opiate immunoassay test will detect morphine, codeine and related 
compounds. This concept is called cross reactivity and whilst in some instances it is advantageous it can 
result in false positives. This occurs where a structurally related chemical, but not one from the specific 
class, gives a positive result due to cross reactivity. Because of the possibility of cross reactivity and false 
positives, all specimens testing positive by immunoassay must be confirmed by a laboratory based 
confirmatory method (e.g. GC-MS or LC-MS) in order to produce a legally defensible result.  
4.4.3: Accuracy, Sensitivity and Specificity 
When evaluating onsite drug tests the terms specificity, sensitivity and accuracy are used to measure 
the capability of the test.  
Specificity 
The specificity of the test can be described as the ability of the test to return a negative test result 
(absence of the drug) when it should. The mathematical formula for this is as follows: 
TN/TN+FP 
Where TN is true negative and FP is false positive 
A test with a specificity of 100% would be expected to give a negative result every time it is used to test 
a truly negative specimen. A test which has a specificity of 90% will give a false positive result 10% of the 
time and so on. However as all preliminary testing must be confirmed by a confirmatory technique 
which is 100% specific, such false positives will be detected by confirmatory laboratory testing. 
Sensitivity 
The sensitivity of the test can be described as the ability of the test to return a positive test result 
(presence of the drug) when it should. The mathematical formula for this is as follows: 
TP/TP+FN 
Where TP is true positive and FN is false negative 
A test with a sensitivity of 100% will give a positive result every time it is used to test a truly positive 
sample. A test which has a sensitivity of 90% will give a false negative result 10% of the time and so on. 
This could result in failure to detect DUID by a chemical test. Impairment testing could be used in 
circumstances such as this. 
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Accuracy 
Accuracy is a mathematical combination of specificity and sensitivity and is the measure of the tests 
ability to return the correct result whether it is positive or negative. The formula used for this calculation 
is as follows;  
TP +TN /TP+ TN + FP +FN  
Where TP is true positive, TN is true negative, FP is false positive and FN is false negative 
The ROSITA project (See Chapter 5) set the sensitivity and specificity requirements for onsite tests at 
greater than 90% and the accuracy at greater than 95%. The DRUID Project (See Chapter 1 and 5) set the 
criteria of greater than 80% for specificity, sensitivity and accuracy. 
4.5: Drugs in Oral Fluid by Class 
4.5.1: Cannabinoids 
Cannabinoids in saliva often result from residual cannabinoids left in the mouth during smoking of 
Cannabis products. The presence of THC through passive exposure is possible and has been reported 
[28, 30]. The main component which is targeted is THC, however recent studies have shown the 
metabolite, THCA, is detectable in picogram quantities in oral fluid. Cone et al. found the saliva: plasma 
ratio of THC to be 10 after smoking [31]. The presence of THC in oral fluid is an indication of recent use. 
Oral fluid cut-offs for cannabinioids tend to be ca. 10-25ng/ml. 
4.5.2: Benzodiazepines 
The saliva: plasma ratio for the benzodiazepines is low (range 0.01 to 0.08). This is due to acidic pKa’s 
and high protein binding (95-99%)  [20]. As a result these compounds are difficult to detect in oral fluid 
and cut-offs need to be low e.g. 10-25ng/ml.  
4.5.3: Opiates 
The common opiates such as morphine and codeine are all detectable in oral fluid. Oral fluid is an 
excellent specimen for detecting heroin use as the metabolite 6-AM is readily detected. Reported saliva 
to plasma ratios for 6-AM, Morphine and Codeine were 0.12 to 7.2 [23], 0.1 to 1.82 [23] and ca. 3.0 [31] 
respectively . Oral fluid cut-offs for opiates tend to be ca. 10-40ng/ml. 
4.5.4: Methadone 
Methadone is detectable in oral fluid and as it is only available in linctus form it can be present in the 
oral cavity at the time of dosing. Saliva: plasma ratios of 0.6 to 7.2 have been reported for the pH range 
5.0 to 7.0 [32]. Oral fluid cut-offs for opiates tend to be ca. 10-40ng/ml. 
4.5.5: Cocaine 
The parent drug is the major analyte in oral fluid. As noted earlier as the saliva pH changes from 5 to 7.8, 
the saliva to plasma ratio for Cocaine varies from 273 to 0.44 [21]. The DRUID study found that the 
sensitivity for cocaine was very low (average 36%) [10].  Oral fluid cut-offs for cocaine tends to be ca. 10-
30ng/ml. 
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4.5.6: Amphetamines, Methamphetamines and Ecstasy (MDMA) 
Typically the parent drug is found in oral fluid for these compounds and the saliva: plasma ratios are 
reasonably favourable, for drug detection in oral fluid, being reported at 2.76 for amphetamine, 3.98 for 
methamphetamine [33]  and 18.1 for MDMA [34] . Oral fluid cut-offs for amphetamines tend to be ca. 
25-50ng/ml. 
4.6: Confirmatory Laboratory Testing for Drug Detection in Oral Fluid 
The currently available roadside chemical tests are based on immunoassays and will give presumptive 
results and so the roadside result alone is not conclusive. The possibility that a false positive result will 
occur cannot not be ruled out when conducting roadside tests and where tests on devices have 
specificity levels of less than 100% this is inevitable. Because of this, there will always be a need to 
conduct a confirmatory drug analysis. Such tests can only be conducted in laboratory facilities by 
laboratories which are specialised in such testing.  
4.6.1: Specimen Selection 
The type of legislation has an impact on the specimen(s) chosen for confirmatory analysis. An example 
would be a zero tolerance type law. If the law requires that the presence of a drug or drugs be 
confirmed, an oral fluid specimen could be appropriate for confirmatory testing. While it may be more 
challenging for the laboratory due to the fact that drug concentrations are lower and therefore harder 
to detect in oral fluid than in urine or blood. Some jurisdictions have commenced using oral fluid as a 
confirmatory specimen. Urine and blood are also suitable specimen types for confirmatory analysis in a 
zero tolerance type law. 
There is no consensus on appropriate per se levels for drugs in blood due to insufficient research in this 
area, although some jurisdictions have introduced levels [35]. However, if per se levels were included in 
legislation for a particular drug(s) they would need to be based on blood drug concentrations due to 
relationship between blood drug concentrations and impairment (See Chapter 3). Therefore it would not 
be appropriate to use oral fluid or urine for confirmatory analysis and instead a blood specimen would 
be required. 
Requirements as currently exist for the collection of urine and blood in terms of chain of custody and 
sample integrity would also apply to oral fluid collection. In addition, sample stability would be a 
requirement and the addition of a suitable preservative will be necessary. 
4.6.2: Blood and Urine Specimen Collection for Laboratory Testing 
Well established procedures for the collection of blood and urine exist and so will not be dealt with 
here. 
4.6.3: Oral Fluid Specimen Collection for Laboratory Testing 
For the roadside chemical test the volume of oral fluid collected is small and can range from 5µL to ca. 
500µL. The specimen collection is not intended for anything other than the performance of the roadside 
chemical test. The collection of an oral fluid specimen for confirmatory testing is a separate process. It 
will normally involve a separate collection device which has the ability to collect a larger volume of oral 
fluid (1ml). Some devices include an indicator of the volume.  The specimen collection device will 
41 
normally consist of a dry absorbent pad which when placed in the mouth will soak up oral fluid. This pad 
is then transferred to a collection tube which contains a buffer and preservative. The collection tube will 
have screw/press-in cap which can be placed on top and secured. An integrity seal can be placed over 
the tube or alternatively the tube can be placed in another container which can be integrity sealed, the 
latter being the current practice under the RTA for blood and urine. Some devices stimulate saliva 
production in order to speed up specimen collection. This can be achieved by using citric acid, chewing 
gum and other agents. There has been a move away from this approach as there is no net gain in the 
concentration of drug in the fluid, instead only the specimen volume is higher, with a lower 
concentration of drug as the oral fluid has been unnaturally stimulated. It should be stated that to a 
certain extent oral fluid production will be stimulated by the placement of a collector in the mouth. 
Specimen collection volume in the case where oral fluid is used as the evidential sample is very 
important. The exact volume must be known or estimated accurately in order to provide a quantitative 
result. This is often achieved by weighing the specimen. Current law permits splitting of the blood/urine 
specimen so that one portion can be anlaysed by the MBRS and the other offered to the arrested person 
for separate analysis by their own arrangement. Similar consideration would have to be given to the 
option of a second specimen if oral fluid were to be used for confirmatory testing. 
If it is collected as an alternative to urine or blood then it could be collected at the roadside by a Garda, 
sealed to ensure its integrity and sent under chain of custody for confirmatory testing. This could 
eliminate the need for blood or urine specimen collection by a Doctor or Nurse at a Garda station. 
In the case of devices which are used for confirmatory testing in the laboratory, recovery of drugs is a 
consideration. Certain drugs such as THC, the active component of cannabis has been known to adhere 
to the collectors and therefore is not available for analysis and the end result is poor recovery [17]. 
Specimen collection device manufacturers have addressed the problem by reducing the binding of drugs 
onto the surface of collection devices by using liquid buffers. These buffers have the advantage of 
reducing the viscosity of the oral fluid making it easier to work with during subsequent processing. A 
disadvantage of this is that many of the buffers and surfactants used can interfere with the subsequent 
confirmatory analysis increasing phenomena such as matrix effects [36] . Device materials and buffers 
are proprietary and it is not possible to predict when recovery might be an issue.  
4.6.4: Stability of Oral Fluid for Confirmatory Testing 
As there may be a period of time between specimen collection and confirmatory testing in the 
laboratory the stability of drugs in oral fluid is extremely important. Also, samples may have to be stored 
for possible reanalysis at some later date. Stability and oral fluid is very much collection device 
dependent [37]. Drug instability can arise from spontaneous hydrolysis of drugs such as cocaine and 
heroin [38] and conversion of nitrobenzodiazepines to their seven amino metabolites [39]. In the 
collection of urine or blood in Ireland, sodium fluoride salt is added to specimen collection vessels in 
order to stabilise the specimen once collected. The addition of sodium fluoride to oral fluid helps to 
reduce the degradation of nitrobenzodiazepines. Other stability problems with oral fluid collection have 
been noted for THC [40] and the methadone metabolite EDDP [41]. 
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4.6.5: Test Equipment 
The equipment that is most suitable for laboratory based confirmatory testing is GC-MS(-MS) or LC-MS(-
MS). This specialist equipment, which the MBRS has operating in its laboratory, is currently in use for 
confirmatory testing of drugs in blood and urine specimens take under the Road Traffic Act. Were oral 
fluid to be a specimen for confirmation the MBRS could adapt existing methods to detect drugs in oral 
fluid. 
4.7: Conclusion 
Whilst oral fluid is suitable for roadside chemical testing it is not recommended for confirmatory testing 
at this stage. In the future as technology and the understanding of the relationship between drugs and 
oral fluid advances it may become a suitable specimen type.  
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Chapter 5: Previous Studies and the Current Status of Roadside Drug 
Testing 
5.1: Introduction 
The search for suitable roadside chemical testing devices has been continuing over the past two 
decades. There have been several international research projects conducted on various aspects of drugs 
and driving and the following projects have included evaluation work on the status of roadside drug 
testing devices. Each study has recognised the need for further improvements.  
An outline of the findings of each of these studies is presented below. 
5.2: ROSITA 1 (1999-2000) 
ROSITA was an acronym for ROadSIde Testing Assessment. The ROSITA 1 project evaluated 19 roadside 
drug testing devices (15 onsite urine devices, 3 oral fluid and 1 sweat device) in 8 European countries 
[42].  The proposed analytical criteria was set at a sensitivity of greater than 90%, a specificity of greater 
than 90% and an accuracy of greater than 95%. Over 2,900 specimens were collected and tested in 
these trials. Oral fluid was the overall preferred specimen for roadside collection in 6 of the countries, 
with urine preferred in Italy and sweat preferred in Germany by the police operators.  
The conclusion of ROSITA 1 was that the sensitivity, specificity and accuracy of the oral fluid devices did 
not meet the criteria as set out, criteria which is achievable with blood analysis by GC-MS in a 
laboratory.   
5.3: IMMORTAL (2002-2005) 
The IMMORTAL project was an acronym for Impaired Motorists, Method Of Roadside Testing and 
Assessment for Licensing [43]. It was established to:  
1. Investigate the accident risk associated with different forms of driver impairment.  
2. Investigate the influence of chronic and acute impairment in order to make a more accurate risk 
assessment. 
3. Recommend criteria for high risk categories and to improve key information to support EU 
policy on licensing and roadside testing. 
This study did not evaluate roadside chemical tests, however the study noted that roadside testing 
needed further improvement as both the drug recognition method (impairment testing) and the 
roadside testing devices still seemed to be ‘error prone’. 
5.4: ROSITA 2 (2003-2006) 
The Rosita 2 project followed on from the ROSITA 1 project and was carried out to evaluate the available 
onsite devices for the detection of drugs in oral fluid [22].  The project was funded by the European 
Commission and was conducted by 6 European countries and 4 states in the USA. A total of 9 devices 
were evaluated in the ROSITA 2 project. The proposed analytical criteria set out in ROSITA 1 were 
applied to ROSITA 2 (sensitivity >90%, specificity >90% and accuracy >95%). An oral fluid sample was 
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taken for analysis using an on-site device and an additional oral fluid sample was taken with a collection 
device for confirmation analysis in a laboratory. At the same time a blood sample was also taken for 
confirmation analysis in a laboratory. The onsite test was conducted by a police officer. Subjects who 
the officer had a suspicion of driving under the influence of drugs were asked to participate in the study 
on a voluntary basis.  In total 2,605 test evaluations were performed on the 9 devices.  All of the devices 
evaluated were tested for the following drugs:   
 Amphetamines  
 Methamphetamines  
 Cannabis    
 Cocaine  
 Opiates  
Three of the devices were also tested for benzodiazepines. 
The operational evaluation by the users varied with problems outlined such as:  
 Procedure long and complicated  
 Test must be read by an instrument 
 Reading of test strips difficult 
 Sample collection was too complicated 
 Device could be out-smarted by the tested person 
 Problems of use in cold and rainy weather  
The analytical evaluation was conducted to measure sensitivity, specificity and accuracy of the devices.  
The conclusion from ROSITA 2 was that no device met the criteria as set out in ROSITA 1 of sensitivity 
and specificity >90% and accuracy >95%. At the end of the study, no device was considered to be 
reliable enough in order to be recommended for roadside screening of drivers. 
5.5: ESTHER (2006-2009) 
ESTHER was an acronym for Evaluation of oral fluid Screening devices by TISPOL to Harmonise  European  
Police Requirements [44]. The ESTHER project was part of the overall DRUID programme (See section 
5.6). In all 13 devices were evaluated by police in 6 different countries and Ireland participated in this 
project. The devices were tested in two different phases and were tested for operational aspects such 
as: 
 Specimen collection time 
 Analysis time 
 Hygiene 
 User experience in terms of successful completion of the test 
 User experience of the simplicity of the test 
 The reliability of the test result indication (lines) 
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The devices were not evaluated for analytical specificity, sensitivity or accuracy. From phase 1, 5 devices 
were recommended for further ‘analytical reliability’ testing. This project also identified requirements 
for training of police officers on the use of oral fluid screening devices. 
At the end of the project it was concluded that the Cozart DDS and Draeger Drug Test 5000 showed 
promise, from a practical perspective, for use during daily traffic law enforcement activities. Also, the 
Biosensor BIOSENS showed promise for use during very specific activities where large numbers of 
people require testing in a limited period of time e.g. raves and festivals. 
5.6: DRUID (2006-2011) 
The DRUID project was previously mentioned in Chapter 1. DRUID was an acronym for Driving Under the 
Influence of Drugs. The DRUID project was an international research project funded by the EU in which 
several different countries in Europe collaborated in 7 different work packages relating to aspects of 
drug and driving [10]. 
There was a scientific evaluation of the available screening devices carried out as part of the 
enforcement work package.  For this scientific evaluation, 8 devices were evaluated in Belgium, Finland 
and the Netherlands for their reliability and accuracy. This work was carried out between October 2007 
and December 2009. The performance of the tests was assessed based on sensitivity, specificity and 
accuracy for the individual drug tests of the devices. The criteria used in the ROSITA projects were eased 
and instead the DRUID project opted for sensitivity, specificity and accuracy of greater than 80%. The 
cut-offs were set to allow optimal detection of drug positive cases. The cut-offs are shown in table 5.1 
below. 
Drug Cut-off (ng/mL) 
Cannabis 1 
Benzodiazepines 1-5 
Opiates 20 
Cocaine 10 
Amphetamine 25 
Methamphetamine 25 
Table 5.1: DRUID project oral fluid testing device cut-offs 
The on-site devices were evaluated by comparison of the oral fluid result of the device with the 
confirmation result of oral fluid collected at same time and sent to a confirmatory laboratory.  All oral 
fluid samples analysed in the laboratory were stored at -20oC until analysed.  Analysis was carried out 
within one month of collection. Comparisons were made against blood specimens in some instances, 
such as the specimens from roadside police tests in Finland and in the Netherlands, however knowledge 
of oral fluid: blood ratios for drugs is still developing and the data available is limited. For some tests 
there were too few positive cases (methamphetamine/MDMA and PCP). There was also a lack of 
cocaine found in tests in Finland, benzodiazepines in the Netherlands and amphetamines/ 
methamphetamines in the Netherlands and Belgium. This demonstrated that the prevalence of drugs in 
individual countries is an important factor in deciding which drugs should be targeted for detection. 
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Several device failures were noted in the study with variety of reasons for the failures such as, incorrect 
operation of the device or only part of the device was successful. Some devices appeared to fail 
completely and some were stopped because it took too long to collect the sample at the roadside. It is 
worth noting that within a drug class (e.g. benzodiazepines) the on-site tests do not necessarily cover all 
the members of that drug class. A high degree of cross-reactivity for the different members of a drug 
class improves the detection capability of the device for that drug class. The manufacturers often test 
the cross-reactivity of many compounds within a drug class; however they may not always do so 
exhaustively. None of the devices reached the target of greater than 80% for sensitivity, specificity and 
accuracy for all drugs. 
DRUID concluded that while the devices showed improvements in general from the devices tested in 
ROSITA 1 & 2 trials there was still room for improvement. The study also showed that the Draeger 
Drugtest 5000 system gave a sensitivity and specificity of greater than 80% for cannabis, meeting the 
DRUID criteria [45].  The suggestion was that the device intended for national use should consider the 
expected types of drugs and their prevalence in the DUID population and choose a device that has the 
best overall performance for those substances.  
While these international trials were ongoing several countries commenced using the existing oral fluid 
devices knowing that the devices would be issuing a high number of false negatives and adopting the 
approach that using the technology which can give a number of false positives is better than identifying 
no drugs in drivers at all. 
5.6.1: Developments Since Publication of the DRUID Findings 
A Belgian study (2012) arising from their participation in DRUID reported on the analytical evaluation of 
4 on-site oral fluid drug testing devices [46].  This study indicated that all tests showed good specificity 
but more improvement in the area of sensitivity is required.   
5.7: Conclusion 
A number of projects have been conducted in the EU and have improved the understanding of how oral 
fluid testing at the road side is operated and how the tests perform. ROSITA 1 and 2 were useful projects 
and most likely were of great benefit to device manufacturers who used the outcomes of these projects 
to develop and improve their products. These projects highlighted that at the time of completion a 
roadside test that could match a laboratory based test was not available in terms of specificity, 
sensitivity and accuracy criteria set by the projects.  The DRUID project built on these studies and while 
there has been no breakthrough in terms of a device being specific, sensitive and accurate for all drugs 
the most recent drug study shows that there are roadside oral fluid chemical testing devices, that are 
capable of meeting the DRUID criteria for cannabis testing. Manufacturers are still involved in improving 
their devices. The ESTHER project is useful as it sets out the requirements of the training of operators of 
roadside oral fluid tests. 
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Chapter 6: Review of Selected Current Roadside Testing Devices 
6.1: Introduction 
As part of the request from the DTTAS the MBRS decided to review a number of representative roadside 
chemical testing systems. The objective of this review was not to perform a critical review of the devices 
but instead to: 
 Gain a better understanding of the scientific basis of the tests 
 Gain a better understanding of the format and operation of the systems 
 Identify the cut-offs that the devices are able to operate to  
 Identify costs of the systems 
 Identify jurisdictions using the devices 
 Identify challenges that may have been encountered with the particular devices 
 Get the most up to date information available directly from the manufacturers, including any 
updates on developments since the completion of the DRUID project, where applicable 
To date a complete type approval specification for these devices has not been drawn up by either the 
OIML (International Organization for Legal Metrology) or CEN (European Committee for 
Standardization).  
Guide to type approval for preliminary drug testing devices was published by the Home Office in the UK 
[27]. This document is similar to the current guide type for the evidential breath testing systems; 
however the UK specification is concerned with a device or instrument for use in a police station and not 
for use at the roadside. To date, no oral fluid drug testing systems have been approved by the Home 
Office but this process is ongoing and it is noteworthy that the guide to type for preliminary drug testing 
devices specified the use of a reader. 
The manufacturers and devices chosen for review were: 
 Securetec Drugwipe 
 Draeger  Drugtest 5000 
 Alere DDS2 
 Mavand Rapid Stat 
All of the manufacturers selected have devices which are currently used by police forces and they all use 
immunoassay technology which can simultaneously detect several different drugs from a single oral 
fluid specimen.  They are all designed for single use in the form of a disposable cartridge with minimal 
steps required by the operator.  The different test devices require different numbers of steps to be 
taken by the operator and some of which are timed steps with the exact time specified. The oral fluid is 
collected using a collector which can be combined with or used separately to the testing cartridge. The 
oral fluid is applied to the immunoassay strip which contains the actual test. In some cases the oral fluid 
is combined with a buffer solution before application onto the immunoassay strip, in other formats the 
oral fluid is applied to the strip and then the buffer is introduced upstream from the site of specimen 
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application. In some cases the tests are incubated at specific temperatures while others operate at 
ambient temperatures. The effect of temperature may also influence the ability of the test to operate 
successfully and can also influence the speed at which the test occurs.   
The devices that the MBRS researched are in use for roadside testing by police forces in certain 
jurisdictions internationally. Each country set out the drugs targeted and the individual cut-offs for the 
targeted drugs.  Some countries have specified a collection time for the oral fluid and others have 
specified a test time for the tester. Some have specified an electronic device and others have requested 
devices which can be read visually and that do not require an electronic device. These specifications are 
usually set out in the relevant tender documents. Such documents tend to apply specifications based on 
what is known to be currently achievable. 
6.2: Securetec Drugwipe 
Securetec are the manufacturer of the Drugwipe and they produce custom made disposable testers in 
the form of a cartridge for different police forces in different countries. The results from this device can 
be read visually or with the aid of an electronic analyser. 
6.2.1: Operation of Device 
The device consists of a test device, with a cover containing an integrated oral fluid collector, this can be 
removed, a specimen can be collected and the collector is returned to the test device. When oral fluid is 
collected, a colour indicator shows that the specimen has been collected successfully. Oral fluid 
collection takes ca. 5 seconds. There is buffer capsule which when broken releases buffer down the 
immunoassay strips and moves the specimen towards the test area. The operator is requested to keep 
the device vertical for 15 seconds after breaking the buffer capsule and then the operator must move a 
sliding cover, which is part of the device, over the test area. The device is then left flat on a horizontal 
surface. The test takes 8 minutes to develop before a result can be read. The results are then 
interpreted depending on the presence or absence of a series of red lines, with the absence of a line 
indicating that the drug is present; and the presence of the line indicating that the drug is absent.  
6.2.2: Countries Which Use the Device 
Securetec have also produced a tester for cannabis and cocaine for Spain, cannabis and 
methamphetamines for Australia and cannabis and amphetamines for East German states. In addition 
they have the Drugwipe5 which is a tester for cannabis, amphetamines, methamphetamines, opiates 
and cocaine which is used in France and Belgium. They have produced a Drugwipe6 for use in Finland. 
The additional drug class that is included in the latter tester is benzodiazepines.  
6.2.3: Device Cut-offs  
The cut-offs for all reviewed manufacturers tests are shown in Table 6.1. Since the DRUID evaluation 
Securetec have managed to reduce the cut-off for the cannabis test and they are claiming that they can 
achieve a cut-off of 10ng/ml. A French tender document specified a cut-off of 15ng/ml for their device. 
The manufacturer claims that the lower the cut-off required the longer the test time of the device.  The 
Belgian device has a cannabis cut-off of 25ng/ml. The Drugwipe used in Australia has a cut-off of 
30ng/ml for cannabis [47]. 
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Drug Securetec Drugwipe 
Cut-offs (ng/mL) 
Draeger Drugtest 
5000 Cut-offs (ng/mL) 
Alere DDS 2 Cut-
offs (ng/mL) 
Mavand RapiSTAT 
Cut-offs (ng/mL)  
Cannabis 10-30 5-10*/25 10*/25 15 
Benzodiazepines n/a 10 20 25 
Opiates n/a 40 40 10 
Cocaine 30 30 30 10 
Methadone n/a 50 n/a n/a 
Amphetamines 40 40 50 25 
Methamphetamines 40 40 50 25 
Table 6.1: Drug cut-offs by manufacturer and device in ng/mL. *Lower cut-offs require longer time.  
6.2.4: Electronic Reader/Analyser 
The Drugwipe tester can also be read using a proprietary electronic reader called the DrugRead. This is a 
hand held (two hands) portable device. The DrugRead offers precise time keeping for the time 
controlled test and provides a clear result. In the case of the Drugwipe there are two steps which are 
time critical and the automatic reader controls these for the police officer. It also has the capacity to self 
test and to be calibrated. A wireless printer is also available. 
6.2.5: Storage and Operation Conditions 
Storage conditions and temperature range for use are important considerations. The recommended 
temperature range is 15°C to 35°C. The recommended shelf life depends on the storage conditions  
which is 6 hours at 0°C to 40°C, for 3 days is 5°C to 35°C and for 2 years is 5°C to 25°C. 
6.3: Draeger DrugTest 5000 Analyser 
Draeger are the manufacturers of the DrugTest 5000 analyser. This is a powered portable module 
intended for use in combination with the Drugtest 5000 test kits. It is not handheld but can be easily 
used from the boot of a car.  A wireless printer is also available.  
6.3.1: Operation of Device 
The test kits are cassettes with a collector module and the immunoassay test strips.  A separate buffer 
cartridge is also used in the analyser. For sampling, the operator instructs the donor to provide and oral 
fluid sample and after 1 minute the operator inspects the sample collector. If after this time the 
indicator has not turned blue then insufficient oral fluid has been collected and the donor is required to 
provide more. Sampling can continue for a further 3 minutes. The operator places the test cassette in 
the lower compartment of the analyser and the buffer cartridge in the upper compartment.  Closing the 
door will then start the analysis automatically.  The operator can see if the cassette is in date as this is 
read along with kit batch number and the number of drugs being tested. The results are issued as either 
named drug detected or not detected. Results are available within 8 minutes. 
6.3.2: Countries Which Use the Device 
It is approved for use in Portugal, Poland and Germany 
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6.3.3: Device Cut-offs  
The cut-offs for all reviewed manufacturers tests are shown in Table 6.1. The cut-off for cannabis has 
also been reduced since DRUID evaluations.  The production of a new antibody means that Draeger can 
offer a cut-off range between 5 and 25ng/ml, however the trade-off is again with the test time of the 
analyser, 5-15ng/ml takes less than 8 minutes, at 25ng/mL it takes less than 5 minutes.  
6.3.4: Electronic Reader/Analyser 
The proprietary electronic analyser is used to control temperature and timing of the test and also reads 
and provides the final result without subjectivity. Quality assurance and calibration checks are possible 
with this system. There is also a memory component and a wireless printer available.  The expiry date of 
the cartridge is noted before the test is commenced.  
6.3.5: Storage and Operation Conditions 
The temperature range for the use of this device is not critical as the analyser controls the test 
temperature however, the rating indicates using the device between 5°C to 40°C. The recommended 
storage conditions for the test devices are 4°C to 30°C. Currently the shelf life of a cassette is 12 months.  
6.4: Alere DDS2 
Concateno, a subsidiary of Alere, manufacture the DDS2.  It is a portable, handheld device intended for 
use with the Alere DDS 2 test cartridge. The test cartridge contains dried reagents, the buffer and the 
immunoassay test strips. The collection device is separate.  The vendor is currently offering 2 different 
test cartridges, a 5 drug panel and a 6 drug panel. The 6 panel drug test includes amphetamine, 
benzodiazepine, THC, cocaine metabolite, methamphetamine and opiates.   
6.4.1: Operation of Device 
The test cartridge must first be inserted into the device and then the driver is asked to provide an oral 
fluid sample. The collection time is 1 minute. The sample collector is then inserted into the test cartridge 
within the analyser. Analysis takes approx 5 minutes depending on the cut-off chosen. 
6.4.2: Countries Which Use the Device 
Its predecessor was the Cozart DDS device which is currently being used in Australia, Spain, Italy and 
Croatia.  The new generation DDS2 device is currently under evaluation in Australia, Spain and Italy. 
6.4.3: Device Cut-offs 
The cut-offs for all reviewed manufacturers tests are shown in Table 6.1. The THC cut-off is dependent 
on the amount of time given for the test to develop in the analyser. A cut-off for THC of 25ng/ml is 
possible with a 5 minute test time. A THC cut-off of 10ng/ml is possible with the longer test time of 9 
minutes. 
6.4.4: Electronic Reader/Analyser 
The proprietary analyser controls the temperature and timings. It is possible to run QC cartridges to 
check that the analyser is performing correctly.  It also can be used with a wireless printer.  
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6.4.5: Storage and Operation Conditions 
The test cartridge can be stored at temperatures of 15-25°C. Stability studies are currently being carried 
out and it is anticipated that the expiry date will be at least 18 months.  
6.5: Mavand Rapid STAT 
Mavand manufacture the Rapid STAT which is a disposable unpowered system comprising of a sample 
collector, a buffer bottle and a test cassette combined in a ‘One-Hand-Clip’ System. The test cassette 
contains two reaction chambers and the test strips. The devices can be manufactured to test for 
between 2 to 7 drugs. The 7 possible drugs which can be tested for are amphetamines, benzodiazepines, 
cocaine, methadone, methamphetamine/MDMA, opiates and THC. 
6.5.1: Operation of Device 
Following collection of the oral fluid the sponge of the collector is washed out in the buffer bottle, this 
buffer-saliva solution is then introduced to the reaction chambers containing the antibodies and allowed 
to incubate for 4 minutes. This solution is then released onto the test strips and the results can be 
evaluated after 8 minutes. The results are then visually interpreted by checking for the presence or 
absence of lines on the strips opposite the name of the drug on the cartridge. The collector contains an 
unspecified compound which stimulates saliva production. 
6.5.2: Countries Which Use the Device 
This device is currently in use as a roadside chemical test by the North Rhine-Westphalia police in 
Germany and was used by French authorities from 2008 to 2011. 
6.5.3: Device Cut-offs 
The cut-offs for all reviewed manufacturers tests are shown in Table 6.1.   
6.5.4: Electronic Reader/Analyser 
Mavand produce a desktop reader requiring a PC, a mobile reader and a desktop reader with integrated 
PC. The desktop reader can have a computer keyboard and printer attached, while the mobile reader 
has an integrated ‘touch sensitive’ tablet PC and portable thermal printer.  All the steps outlined above 
are still carried out away from the reader and the cassette is inserted into the reader which contains a 
camera with a sensor which measures the intensity of the colour lines and provides an objective result. 
6.5.5: Storage Conditions 
Use of this system should ideally be between 15°C to 35°C. The recommended storage temperature is 
between 2°C to 30°C. The shelf-life is set by the expiry on the packaging which normally extends to 1 
year from purchase.  
6.6: Costs of Tests and Analysers  
The costs for the tests were provided by the manufacturers and these are summarised in Table 6.2. This 
table also includes the cost of the readers/analysers. It is important to point out that these are costs 
provided for estimate purposes only and are not to be construed as quoted prices. Until the numbers of 
readers and tests and indeed the format of the tests (1 drug or multiple drugs) are decided it is not 
possible to put a figure on the final cost of introducing any one of these systems. The cost will also 
depend on whether the cassette or test cartridge is custom made or is similar to other jurisdictions. In 
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some cases it may also be possible to offset the cost of the reader/analysers against the cost of the tests 
themselves and spread the cost over the lifetime of a contract arising from a successful tender bid.  
Unit Cost Devices 
5-7 drug test cartridge €10-€20 
Reader/Analyser €2000-€4000 
Table 6.2: Unit Costs for Devices 
If the disposable materials are taken into account alone the cost of a drug test at the roadside is 
significantly more expensive by a factor of 60 to 125 times the cost of a roadside alcohol breath test. 
This is based on the roadside breath alcohol test mouth piece costing approximately 16 cent and the 
roadside drug testing disposable cartridge cost of €10 to €20. However, if the overall costs are assessed 
(to include equipment purchase, depreciation, maintenance etc.) this differential is reduced to 
approximately 10 to 20 times more expensive than a roadside alcohol breath test, depending on 
whether or not the roadside drug test includes an electronic reader. The fact that the devices test for 
between 5-7 drugs rather than just a single drug as with alcohol should also be taken into account when 
considering costs.  
6.7: Conclusion 
The 4 devices were selected to demonstrate the variety of test devices available and their different 
operational requirements. They illustrate the complexity of drug testing compared to the simplicity of 
alcohol breath testing. They also highlight some of the considerations that will need to be addressed 
when setting out specifications in a tender and procurement process for the approval, supply and 
testing of devices by the MBRS for proposed use in this jurisdiction.  
This review highlighted the importance of selecting devices that have a minimum number of steps and a 
short collection and test time. It also showed that devices capable of detecting the most prevalent drugs 
found in Irish road users, cannabis and benzodiazepines, are available and a number of these devices are 
currently in use for roadside drug testing in other jurisdictions. The drugs targeted are selected by the 
buyer and to date these have been the most prevalent drugs found to impair the driving internationally. 
It is not possible to target all impairing drugs with these devices. 
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Chapter 7: Practices in Other Countries 
7.1: Introduction 
In order to gain the most up to date information on the practices adopted by other jurisdictions in the 
detection of drug drivers the MBRS conducted a survey of scientific colleagues working in the area of 
DUID in 13 countries. The questions posed in this survey covered legislative, practical and scientific 
matters relating to the introduction of roadside oral fluid testing. A copy of the survey questions and a 
summary of the responses can be found in Appendix 1. Information gathered from the survey is 
included here for the relevant jurisdictions. 
In addition the MBRS reviewed the literature to ascertain the current practices in several countries in 
relation to detection of drug drivers at the roadside. The following countries/states are discussed below.  
The following eight countries or jurisdictions either; use oral fluid devices, or are at the tender stage of 
procuring devices: 
1. Australia/State of Victoria 
2. Belgium 
3. Finland 
4. France 
5. Germany 
6. Norway 
7. Denmark 
8. Switzerland 
The remaining five jurisdictions do not currently use roadside drug testing devices and have not 
indicated if they plan to introduce them in future. 
9. Canada 
10. New Zealand 
11. Sweden 
12. UK  
13. USA 
7.2: Australia: State of Victoria 
The Australian state of Victoria was the first jurisdiction to introduce random roadside drug testing, 
beginning in 2004. This legislation includes offences based on observed impairment.  The roadside 
chemical test element of the legislation started with only two drugs in the test kits, methamphetamine 
and THC. In 2006 they introduced MDMA (ecstasy) to this group [48]. 
The procedure at the road side involves an initial test using the Securetec, DrugWipe TWIN and if 
positive for one or both drug groups, another oral fluid test is conducted using a second immunoassay 
device, the ‘Cozart Rapiscan’ which was manufactured by a company now owned by Alere. This second 
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test is conducted in a custom-built vehicle at the roadside adjacent to the checkpoint (see cut-offs in 
table 7.1). If this device also reveals a positive result for either or both drug groups, then drivers are not 
permitted to continue driving their vehicles for a minimum period of 24 hours, and an oral fluid 
specimen is sent to the laboratory for confirmation.  If another oral fluid specimen cannot be provided a 
blood specimen is taken for confirmation testing. The specimen forwarded to the laboratory is tested for 
the two drug groups and also for a further range of drugs.  The presence of one or more of the 
proscribed drugs at any concentration is deemed an offence. The Australian states of New South Wales, 
Queensland, South Australia, Western Australia and Tasmania now conduct similar testing to Victoria.   
 
Device  Target drug  Cut-off (ng/ml) 
DrugWipe TWIN Methamphetamine/MDMA   100 
 THC  30 
Rapiscan Methamphetamine/MDMA 60 
 THC 150 
Table 7.1: The cut-offs used in the State of Victoria, Australia. 
7.3: Belgium  
The legislation permitting the use of oral fluid testing at the roadside was introduced in 2010.  The arrest 
is based on suspicion and not random checks. The Securetec DrugWipe 5 was chosen as the device 
following a procurement exercise.  Before the introduction of this, Belgium had a FIT test, followed then 
by a urine test, as the preliminary roadside test. If positive, there was an immediate administrative 
sanction of disqualification from driving for 6 hours.  A blood specimen was also taken and the 
confirmatory results were used for the ultimate sanction [49].  
Belgian police and scientists conducted an evaluation of on-site oral screening using 3 commercially 
available devices, with the findings of this study published in 2010 [49]. It concluded that the devices 
could detect approximately 70% of all cocaine and cannabis users. Amphetamines were detected more 
easily with a sensitivity of greater than 92%. In approximately 15% of the blood samples analysed, none 
of the analytes mentioned in the Belgian DUID law were detected at a concentration above the legal cut-
off.  While this is undesirable it may be justifiable as confirmatory analysis in a laboratory will ensure 
that no injustice occurs.   
Belgium has decided that the sensitivity currently provided by the manufacturers is high enough for 
their goals, which are: 
 To have a roadside drug test which will have a deterrent effect on drug drivers 
 Decrease the accident risk for all drivers.  
Law enforcement agencies also want to reduce the percentage false positives. The authorities have 
chosen an unpowered device, the police do not use a FIT test, they use a checklist with parameters such 
as emotional state (aggressive, stressed, sleepy etc.), visual signs (eyes, pallor etc.). Based on this 
checklist they quickly screen for possible drug driving suspects. Then the on-site test is performed. If the 
subject is negative for this test and also negative for alcohol, but the police officers’ opinion is that the 
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driver is impaired he/she can still press charges via a special article in the law. This means that a blood 
sample can be drawn and that laboratory analysis can be performed, focusing on drugs or medications 
not tested for by roadside chemical testing such as benzodiazepines. The legislation requires the use of 
oral fluid for confirmation purposes; however it is the understanding of the MBRS that blood specimens 
are still taken and that oral fluid collection has not been finalised.  
The legislation has indicated per se levels for use with blood or oral fluid specimens (table 7.2) and if the 
driver has a level above these he/she is sanctioned.. 
 
 
 
 
 
 
 
 
 
Table 7.2: Belgian per-se levels in oral fluid and blood (CLT=Confirmatory Laboratory Test) 
 
7.4: Finland  
Zero tolerance legislation on illicit drugs and driving was introduced in Finland in 2003. All controlled 
substances, including medicinal drugs such as benzodiazepines, fall within the scope of zero tolerance 
drug laws, if used without a prescription.  Drugs that have a potentially harmful effect on driving ability 
have warning labels on their package [19]. The police are authorised to conduct a breath alcohol test or 
an oral fluid drug test on-site even when no suspicion exists. The devices for onsite testing for alcohol 
and drugs have the same position under the national law.  The main reasons for using roadside drug 
tests are random checks, impaired or dangerous driving, road traffic accidents or information from a 
bystander.  Impairment law remains on the statute books and the police officer can provide evidence of 
impairment using a standardized field sobriety observation sheet.  Any evidence/observations of drug 
use are also documented.  
Finland also participated in the DRUID evaluation of oral fluid drug roadside drug testing devices [50].   
Drugwipe devices have been in regular use by Finnish police for several years and the police officers 
have been satisfied with the operability of the device. Benzodiazepines and amphetamines have been 
identified as the most prevalent substances in suspected DUID cases in Finland for the period 1977-2007 
Specimen type Drug group Cut-off (ng/ml) 
Oral fluid (Roadside) Amphetamine 50 
 Methamphetamine 50 
 Opiates  10 
 Cannabis 25 
 Cocaine  20 
Blood (CLT) Amphetamine 25 
 Methamphetamine 25 
 Opiates  10 
 Cannabis 1 
 Cocaine  25 
Oral Fluid (CLT) Amphetamine 25 
 Methamphetamine 25 
 Opiates  5 
 Cannabis 10 
 Cocaine  10 
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(76% and 46% respectively). THC is also prevalent at 20%.  Previously the Finnish traffic police have been 
using DrugWipe5 and DrugWipe5+ and using a separate Drugwipe single test device for benzodiazepine. 
Finnish police are currently using Drugwipe6 which includes a test strip for benzodiazepines. 
Confirmation of the drug is carried out in the laboratory and a blood specimen is used for this purpose. 
7.5: France  
France introduced roadside drug testing in 2001 using urine tests and in 2008 introduced oral fluid on-
site drug testing. The minimum levels for detection in oral fluid and urine are set out by order and are 
outlined below (Table 7.3). Confirmation tests are carried out using blood specimens and the minimum 
levels of detection for the blood analysis are also set out by order and are also outlined below.  The 
police officer can arrest a driver on the basis of suspicion and a test is also mandatory after a collision or 
if the driver is a traffic offender.  The only drugs specified in legislation are illegal drugs. France awarded 
its first contract for oral fluid devices in August 2008 for a period of three years and in February 2011 
issued a new tender. DrugWipe5 is the oral fluid device chosen from the latest tender. 
 
 
 
 
 
 
 
 
 
Table 7.3: French per-se levels in oral fluid and blood (CLT=Confirmatory Laboratory Test) 
7.6: Germany  
Germany, in 1998, was the first European country to introduce zero tolerance legislation prohibiting 
driving under the influence of the drugs cannabis, cocaine, heroin, morphine, amphetamine and the 
designer drugs MDMA and MDEA [50]. In most Federal States of Germany roadside drug tests have been 
introduced on a routine basis where there is a suspicion of drugs use, these can take the form of a urine, 
sweat or more recently oral fluid screening device. The police officer can arrest a driver on the basis of 
suspicion or conduct a test which is mandatory after a collision.  A police officer can either carry out a 
roadside test or carry out a roadside assessment.  The different police forces are using different devices.  
Of the 4 device manufacturers contacted, 3 were able to give an example of a German police force 
which uses their particular device.   Zero tolerance is for illegal drugs only. Blood specimens are used for 
Specimen type Drug group Cut-off (ng/ml) 
Oral Fluid (roadside) Amphetamine 50 
 Methamphetamine 50 
 Opiates (Morphine/6-AM) 10 
 Cannabis (THC) 15 
 Cocaine/Benzoylecgonine 10 
Urine (roadside) Amphetamine  1000 
 Methamphetamine 1000 
 Opiates (Morphine) 300 
 Cannabis (THCA) 50 
 Cocaine/Benzoylecgonine 300 
Blood (CLT) Amphetamine 50 
 Methamphetamine 50 
 Opiates (Morphine) 20 
 Cannabis (THC)  1 
 Cocaine  50 
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confirmatory purposes and the analytical thresholds are set out in law for the specific drugs in blood 
(Table 7.4) [10, 44].  
 
 
 
 
Table 7.4: German per-se levels in blood (CLT=Confirmatory Laboratory Test) 
 
7.7: Norway 
In February 2012, Norway introduced per se limits into legislation for twenty illegal drugs and medicines 
with an abuse potential.  Norway is the first country to define both impairment based legislative limits 
and limits for graded sanctions for drugs other than alcohol [35]. The impairment limits are specified for 
blood specimens. The police officer can stop a driver at random and conduct a roadside assessment. 
They perform legislation based specific performance impairment tests. Oral fluid roadside testing is 
permitted but has not been implemented as yet.  Norway is conducting a procurement process at 
present.  
The use of the limits does not apply to therapeutic use of medicines with an abuse potential prescribed 
by a doctor. In such cases the assessment is made on the basis of concentration of intoxicant found in 
the blood specimen and the results from the standard medical examination and any other relevant 
information including roadside assessment.  
7.8: Switzerland 
In January 2005 a two tier system based on impairment by any psychoactive substances which affect the 
capacity to drive safely and zero tolerance for certain illicit drugs was introduced [51]. A driver is 
sanctioned when THC, free morphine, cocaine, amphetamine, methamphetamine, MDMA or ecstasy 
and MDEA can be unequivocally detected by toxicological analysis in whole blood. The Federal Roads 
Office (FEDRO) is responsible for the definition of the punishable concentration limits for the controlled 
substances. At present these limits are 1.5ng/ml for THC and 15ng/ml for the other substances.  For all 
other psychoactive substances, in particular medicinal drugs such as benzodiazepines, methadone and 
antidepressants, impairment must be proven.  Evidence of impairment is based on police report, results 
of clinic examination by physician at the time of specimen collection and the results of the toxicological 
analyses of the biological samples. The police report includes observations of impairment and can also 
record results of a breath alcohol test and/or roadside drug test device. A blood specimen can be 
obtained without oral fluid testing on the basis of suspicion.   A blood and/or urine specimen can be 
used for zero tolerance drug detection. Currently Switzerland uses Drugwipe5 for roadside drug testing.  
Specimen type Drug group Cut-off (ng/ml) 
Blood (CLT) Amphetamine 25 
 Methamphetamine 25 
 Opiates (Morphine) 10 
 Cannabis (THC)  1 
 Cocaine/Benzoylecgonine 10/75 
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7.9: Canada 
Section 253 of the Criminal Code of Canada prohibits driving while impaired by alcohol or drugs. In 2008 
the law gave increased powers to the police to test for drugs in drivers. If the police officer is suspicious 
of impaired driving due to the presence of a drug or drugs then he can examine the driver using a field 
impairment test at the roadside and by subsequent tests by drug recognition experts and bodily fluid 
tests provided in the police station. Blood, urine or saliva specimens can be provided in the police 
station or in a hospital. There is a per se limit for alcohol but not for drugs. The law does not specify any 
particular drug but instead includes all impairing drugs. There is no roadside testing device used by the 
police [52]. 
7.10: Denmark 
Until July 2007 DUID legislation in Denmark was based on impairment evaluated on the basis of a clinical 
investigation performed by a physician and toxicological analyses. In July 2007, fixed concentration 
limits in blood for drugs of abuse were introduced into the Danish traffic legislation. The police can now 
stop drivers on suspicion and at random without suspicion. The police are permitted to take an oral fluid 
or sweat sample and to conduct an eye examination. At present oral fluid devices are not in use. The 
fixed concentration limits are based on low therapeutic blood concentrations and on blood 
concentrations expected a short time (hours) after the intake of illicit drugs and not on the analytical 
limits of quantitation based on the analytical equipment used in the laboratory. These limits apply to 
illicit drugs and psychotropic substances with abuse potential registered with the UN conventions. 
Evidence of impairment is still required for prescribed drug drivers and for drugs such as 
benzodiazepines, morphine and methadone which are used both after a prescription and as illicit drugs, 
the fixed concentrations are used for prosecution [53].  
7.11: New Zealand 
The Land Transport Amendment Act 2009 gave police greater powers to deal with the problem of 
driving under the influence of drugs. There are three steps which the police must follow before charging 
a driver with driving while impaired: 
1. Good cause to suspect- i.e. evidence of erratic driving or drivers personal demeanour 
2. Unsatisfactory completion of a compulsory impairment test (CIT) which consist of 3 behavioural 
tests that check whether a driver is impaired 
3. Presence of a drug or drugs in a blood sample 
There is no roadside testing device currently in use by the police in New Zealand. While random 
roadside drug testing is not permitted under this Act and the police do not use roadside drug testing 
devices, police can still require a driver to carry out a CIT if he/she has passed a roadside breath alcohol 
test and is behaving in an intoxicated manner. 
The drugs targeted are opiates, amphetamines, cannabis, sedatives, antidepressants and methadone. 
The list is reviewed from time to time in light of research and changes in drug trends in New Zealand. 
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7.12: Sweden 
The Swedish government introduced zero tolerance for driving with a measurable amount of a 
controlled substance in blood on July 1 1999.  Sweden was the first country to include scheduled 
prescription drugs as part of this legislation. The zero-limit applies whenever a controlled substance is 
unequivocally identified in a specimen of blood and a prosecution is made regardless of whether the 
driver shows signs and symptoms of being under the influence of drugs.  Currently the police do not use 
a roadside chemical test. They have powers to examine a suspect’s eyes with the help of a small 
flashlight and a pupillometer. The police also note responses to questioning and any disturbance of 
speech or gait. The police require a reasonable suspicion to request a blood specimen for toxicological 
analysis. If a medication is used in accordance with a doctor’s prescription the person is exempt from 
prosecution for DUID provided certain conditions are met.  A successful DUID prosecution with only a 
prescription drug in the blood requires proof that the person was overdosing or abusing the medication 
in question and this requires expert testimony [54]. 
The limits of quantitation for the analytical method used serve as the per se threshold concentration 
limits in blood. Analytical results below these limits are reported as negative. Indeed these limits are not 
static and are therefore not written into law because they are likely to change depending on 
developments and improvements in analytical methodology. 
With the introduction of zero limit law and the simple roadside tests of drug influence, there has been a 
tenfold increase in the number of cases being submitted for forensic analysis. The police in Sweden do 
not use roadside chemical test devices for drugs as they do not consider them to be effective and that 
the vast majority of specimens (approximately 85%) sent for toxicological analysis contained one or 
more scheduled drug when the zero tolerance limit was introduced. 
7.13: UK  
The UK has a provision in current legislation for onsite oral fluid roadside drug testing by police officers 
however to date it has not been legally implemented. The North Report has recommended that a device 
to be used in a police station should be approved within two years [11]. The Home office issued formal 
guidelines for type approval in January 2011 with the intention of completing the process in June 2011, 
however to date no device has been approved [27].  At present a police officer on the basis of suspicion 
can perform field impairment tests, which are outlined in the Code of Practice for Preliminary 
Impairment tests. There is no requirement by the police officer to administer the FIT test in order to 
assess impairment.  The North Report recommends that it should be policy to carry out this test in all 
cases where impaired driving is suspected.  The current legislation requires that a physician has to 
determine whether the drug driving suspect has a condition which might be due to a drug. The North 
Report recommendation is to allow nurses to also take on this role. The report has made several 
recommendations including the introduction of impairing levels for named drugs, zero tolerance for 
specified drugs and also to retain the current offence of driving while unfit due to a drug.  North has also 
recommended that once preliminary drug screening devices are type approved for use in police stations 
that the type approval of roadside devices would commence. A bill which is currently going through due 
process in the UK includes specified limits for specified controlled drugs.  
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7.14: USA 
In the USA the police officer can stop a driver on the basis of suspicion of driving under the influence of 
a drug. The officer can check for alcohol at random but not for a drug. There are no onsite drug 
screening devices approved in the USA. The US developed the Drug Recognition Expert (DRE) program 
however it is accepted that the DRE program “as is” is not scalable to the size of the drugged driving 
problem [55].  There are a total of 17 US states that have variations of zero tolerance type legislation 
with regard to DUID. In 7 States, it is illegal to have any amount of prohibited drug or its metabolite in 
the body while operating a motor vehicle. In North Carolina and South Dakota, the per se drugged 
driving laws pertain only to drivers less than 21 years.  In 5 States it is illegal to have any amount of a 
prohibited drug in the body while operating a motor vehicle, in 3 States it is illegal to have specified 
amounts of specified prohibited drugs in the body while operating a motor vehicle. The per se drug law 
in Minnesota does not include cannabis. In 5 States it illegal for any drug addict or habitual use of drugs 
to drive a vehicle in their State [56].    
A number of States use a separate statute for driving under the influence or with impaired driving or 
both. Evidence of impairment is required [57]. Only two States, Alabama and Alaska, have compulsory 
testing in certain circumstances in crashes involving serious injury or death.  Different States stipulate 
the type of specimen that law enforcement officers are authorised to collect. In 34 States it is permitted 
to take blood/urine, 8 States permit only blood, 6 States permit saliva, 8 States permit other bodily 
substances and 3 States do not have a provision for collecting specimen to test for drugs.  From this 
limited review there is a lack of uniformity or consistency in the way individual States approach drugged 
drivers.  One report recommended the standardisation of drugged driving testing in the USA [55].  
7.15: Conclusion 
The Bureau has reviewed the practices in 13 different countries and from this snapshot of countries 
worldwide there is a divergent approach taken to roadside drug testing both in the legislative approach 
and the detection approach by the police officer. The manner and type of device and the number of 
drugs targeted when using oral fluid devices were also diverse. There is a move towards the collection of 
oral fluid and the advancement of oral fluid devices since their introduction by Victoria, Australia in 2004 
to the planned introduction by Norway in 2012 is encouraging. There is a consensus towards zero 
tolerance limits for illegal drugs and the need for evidence of impairment and the confirmed presence of 
a drug if the drug is a medicinal one.  Countries have also included the use of RTIT and have introduced 
oral fluid devices to assist with enforcement of the zero limits.  Oral fluid drug testing devices do not 
replace RTIT. 
The Bureau has gained insight into how other jurisdictions deal with DUID and can now recommend the 
use of oral fluid devices in line with other EU countries.  While there is no EU or international standards 
for the devices, the use of the devices internationally has demonstrated their general fit for purpose 
status. The Bureau will use the knowledge gained when setting out the device specifications including 
cut-offs and in the legislative provisions required to operate the devices effectively. There will have to 
be particular care and attention to the legal and operational requirements of the Irish Courts. 
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Chapter 8: Considerations and Options for Roadside Drug Testing 
8.1: Introduction 
In the preceding chapters we have considered; the effects of drugs on driving and the relationship 
between impairment and bodily fluids; detection of driving under the influence of drugs; previous 
studies and the status of roadside drug testing. We reviewed the selected current roadside chemical 
testing devices, as well as practices in other countries. We now consider the options to progress the 
detection, enforcement and prosecution of driving under the influence of drugs other than alcohol and 
four components must be considered:  
 Legal 
 Operational 
 Scientific  
 Medical 
8.2: Legal Considerations 
8.2.1: Type of Drug Driving Legislation Required  
8.2.1.1: Impairment Approach  
This is the current approach where the driver is arrested if the Garda is suspicious that the driver is 
under the influence of an intoxicant to such an extent as to be incapable of having proper control of the 
vehicle.  The Garda has to prove driver impairment.  No additional test either RTIT or chemical testing, is 
currently conducted. This approach does not support random roadside checking. 
8.2.1.2: The Zero Tolerance Approach 
 A zero tolerance approach is where a zero limit is applied to controlled substances and any measurable 
amount of a controlled substance which is unequivocally identified in a specimen of blood/urine or oral 
fluid of the driver and a prosecution is made regardless of whether the driver showed signs and/or 
symptoms of being under the influence of drugs. The introduction of a zero tolerance will also apply to 
controlled drugs which, if authorised and requiring to be used in accordance with a prescription or 
medical or healthcare advice, are not so used. This approach gives rise to consideration that some 
drivers may have the confirmed presence of such drugs in their bodies but without evidence of 
impairment. The detection in a driver of such a product known to impair driving skills and thus 
constituting a risk to road safety is an offence under this approach. 
8.2.1.3: Per se Approach 
This approach sets out in law limits for certain classes of drugs such as opiates, cannabis, amphetamines, 
cocaine and benzodiazepines.  This approach is similar to the per se limits for alcohol and it is in its very 
early stages of acceptance within the scientific and legal communities. This approach has not been 
adopted in too many countries. It is difficult to establish such ranges which would represent driving 
impairment in the general population due to the complex nature of how drugs interact with the body 
pharmacodynamically and pharmacokinetically. Appropriate and suitable levels would need to be 
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established but would be subject to variations as between and within individual drivers, tolerance to 
specific drugs, interactions between drugs and an interpretation of a given blood concentration of a 
drug at a specific time when the individual was actively driving. Research is continuing in this area and 
Norway has implemented legislation this year with per se levels set out for 20 named substances [35]. 
8.2.2: Mandatory Intoxicant Testing 
The integration of detection of driving under the influence of alcohol and driving under the influence of 
drugs is a rational and logical development. Currently, the legislation provides for mandatory alcohol 
testing (MAT) only. Legislative provision for mandatory intoxicant testing (MIT) with authorisation for 
establishing MIT checkpoints to test for both alcohol and other drugs would allow for a structured and 
integrated procedural approach.     
8.2.3: Mandatory Testing After a Collision 
Mandatory alcohol testing after a collision was introduced in the 2010 RTA and again this would be the 
integration of both the alcohol and drug driving legislation. See point 8.2.2 above. 
8.2.4: Powers of Detention of Drivers at the Roadside 
The Garda has the legal authority to conduct roadside alcohol testing and this would need to be 
expanded to integrate the roadside drug testing. The period of detention of a driver is also a legal and 
constitutional consideration. The complete RTIT and oral fluid test could be carried out after a breath 
test for alcohol and this would lead to the driver being detained at the roadside for a much longer 
period. See points 8.2.2 & 8.2.3 above. 
8.2.5: Order of Testing at the Roadside  
The integration of the impairment or chemical test conducted at the roadside should be such that it 
does not interfere with the roadside alcohol test but should be part of the overall testing regime. The 
elements of such a regime are shown in Figure 8.1. 
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Figure 8.1: Proposed processing of drivers suspected of driving under the influence of alcohol and/ or drugs in Ireland and the 
type of specimen for analysis 
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8.2.6: Provision of Specimen for Testing 
Provision of an oral fluid specimen is not invasive.  However, privacy rights and, if and when an oral fluid 
specimen is required for confirmation analysis, the requirement for a second specimen from the suspect 
driver (as is the case with existing legislation for alcohol/drug testing) is a consideration at this point. 
Legal considerations should be explored with this possibility in mind. There will always be a need for 
confirmatory analyses. The problem of dry mouth, due to the drug taken or a medical condition, and 
thus the inability to provide the requisite specimen should also be given consideration at this stage.  
8.2.7: Proscribed Protocols for Carrying Out and Recording Drug Testing at the Road Side 
Careful consideration will have to be given to any protocols for roadside chemical testing. The question 
of whether they should be proscribed in legislation with accompanying proscribed forms and 
documentation arises in the context of ongoing research into the different types of drugs and tests 
which may be subject to change over time. The necessity for proscribed record documentation for the 
impairment testing is a different legal consideration. 
8.2.8: Number of Drugs to be Detected if Using a Roadside Drug Testing Device  
The prevalence of drugs will affect choice of targeted drugs and improvements in detection capabilities 
will also be an area for consideration. The number of drugs detected at present in the blood and urine 
specimens analysed is not set out in legislation and is necessarily subject to change especially with 
developing methods and prevalence information. 
8.2.9: Cut-off Levels of Selected Drugs 
In the absence of international agreement on cut-off levels for oral fluid roadside devices the cut-off 
levels will be a matter of either specification by the MBRS or by the level of detection which can be 
achieved by the manufacturers of the devices.  
There is no international acceptance of cut-off levels for laboratory confirmation analysis for blood, 
urine or oral fluid. Some countries have set out limits and more rely on the analytical capabilities of the 
confirmation laboratory. Careful consideration on cut-off selection will still depend on continuous 
monitoring of international best practice for the selected specimen type.   
8.2.10: Approval, Supply and Testing by the MBRS 
Any changes required by legislation in relation to approval, supply and testing will have to be considered 
by the DTTAS and the MBRS. 
8.2.11: Alcohol and Drugs 
Consideration of graded penalties for combinations of intoxicants should be examined in the context of 
graded penalties for alcohol alone as currently exists. 
8.2.12: Legislative Requirements Relating to Medical Fitness to Drive 
Legislative requirements relating to medical fitness to drive and alcohol and drug use and dependency 
are a further area for examination (see Medical Considerations below). 
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8.3: Operational Considerations 
8.3.1: Stand Alone or Electronic Analyser/Reader  
This issue will only require consideration if roadside drug testing is chosen as an option. The pros and 
cons will be set out and considered by the GNTB and MBRS.  
8.3.2: Test Protocols 
The protocol for RTIT has been agreed and documentary recording of the evidence is currently being 
reviewed. A separate test protocol for roadside chemical testing will have to be devised if introduced. 
Careful consideration will need to be given to the documentary recording of the evidence required for 
this preliminary test. 
8.3.4: Selection of Target Drugs for Roadside Chemical Testing Device  
If a chemical test option is chosen then careful consideration will have to be given to the number and 
selection of the targeted drugs. From the information gathered from other countries any number 
between 2 and 7 drugs are currently targeted at the roadside using these devices. The Bureau will 
continue to review the 7 drugs or drug classes that it currently detects and will continue to review the 
prevalence information gathered within the country and internationally to allow appropriate flexibility in 
the choice of drugs targeted with the devices. 
8.3.5: Training in Impairment Testing and Use of Roadside Chemical Testing Device 
Training of Gardaí in RTIT was completed in collaboration with UCD and the MBRS and involved training 
of Garda trainers. This will continue as required.  The training of Gardaí in the use of roadside chemical 
testing devices will be the responsibility of the MBRS as part of the supply of the devices and will be 
conducted on similar lines to the training of Gardaí as operators of the roadside alcohol testing devices. 
The MBRS will train the Garda trainers.  
8.3.6: Costs 
As already mentioned the running costs of using oral fluid roadside tests are significantly more than the 
running costs of breath alcohol roadside tests. If the expected use of the devices were similar to the use 
of the PBT devices then the cost of disposable materials to be used would be between 60 and 125 times 
more expensive.  On the other hand, the cost of purchasing the respective devices and of calibrating 
them must also be factored in as discussed in section 6.6. However, the cost benefit of introducing the 
roadside drug testing devices would be the added significant deterrent factor generated for road safety 
and the improved detection and enforcement rates by the Gardaí in the ever increasing problem of 
drugs driving. The use of the devices will be discussed in the options presented.  
8.4: Scientific Considerations 
8.4.1: Scientific Specifications 
The selection of scientific criteria and the suitability of the current devices to reach these scientific 
specifications such as acceptance criteria for specifcity, sensitivity and levels of detection will need to 
be considered if the way forward is to include roadside chemical testing.  The acceptance rate of false 
positives and false negatives should be assessed in light of acceptance of any legal changes to the 
current system and public confidence in the devices. 
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8.4.2: Cut-off Levels for Each Drug or Drug Class  
The cut-offs should not be confused with measurement of impairment but only considered in light of 
indicating the presence or not of a drug or drugs. The choice of the cut-offs will have to be considered in 
tandem with the confirmatory methods in the laboratory. 
8.4.3: Selection and Testing of the Device 
A testing protocol and specifications for the initial tender and the continuous testing of devices or 
analyser/readers will be required. The set-up of the oral fluid device testing laboratory will then be used 
for continuous quality assurance testing. This could include field trials, laboratory evaluation or 
combination of both. 
8.4.4: Laboratory Confirmatory Analysis 
In all cases confirmatory analysis is required whether the legal approach used is impairment, or zero 
tolerance or per se legislation. Scientific consideration of oral fluid as a specimen for confirmation 
should be made. Blood or urine specimens are currently used.   
 
8.5: Medical Considerations 
8.5.1: Medical Assessment of DUID: 
The necessity for properly trained forensic medical examiners is also part of the DUID strategy.   The 
availability of physicians and nurses trained in the assessment of persons under the influence of drugs 
and able to differentiate from medical conditions mimicking drugs intoxication is another consideration 
and submissions in this regard have been sent to the Department of Justice and Legal Reform and the 
Department of Health and Children [58].  
The Faculty of Forensic and Legal Medicine of the Royal College of Physicians in London has produced 
comprehensive guidelines and pro forma document for the assessment of drivers under the influence of 
intoxicants (“section 4 RTA assessment”) which can be found on the Faculty website at www.fflm.ac.uk 
8.5.2: Medical Fitness to Drive 
Another aspect of driving under the influence of drugs is the necessary connection with assessment of 
medical fitness to drive.    The Driver Vehicle Licensing Authority (DVLA) in the UK and similar bodies in 
jurisdictions such as Australia and Canada as well as other EU countries has set out in detail how such 
guidelines should be implemented and enforced by a Driver Licensing Authority.    This is currently the 
subject of detailed consideration by the Royal College of Physicians of Ireland working group on Road 
Traffic Medicine under the auspices of the National Programme Office for Traffic Medicine (Royal 
College of Physicians of Ireland and Road Safety Authority) of which the MBRS is a member.    There is a 
subgroup of that working group dealing specifically with alcohol and drugs and the working group has a 
representative on the UK Medical Advisory Panel Alcohol and Drugs (Transport).    In any consideration 
of DUID there must be overlap and coherence with licensing requirements and of licence suspension in 
the area of alcohol and drug misuse and dependence.  The relationship between drugs of abuse, 
controlled drugs, prescribed medicines and over the counter medicines in the area of safe driving and 
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road safety is independent of the concepts of legality and should be considered solely in terms of their 
effects on the skills necessary for safe driving.     
A recent High Court case considered the current regulations and the shared duties and responsibilities of 
doctors and patients in assessing and monitoring medical fitness to drive where patients have medical 
conditions and are on prescribed medications [59].  
 
8.6: Options 
8.6.1: Option 1 - Retain the Current Position 
The current situation  is the legal requirement of evidence of impairment by the Garda and the 
confirmed presence of a drug or drugs in a blood or urine specimen provided by the driver in a Garda 
station or in a hospital and analysed by the Medical Bureau of Road Safety.  While this option calls for no 
changes in legislation or in operation nor does it require scientific or medical considerations to be 
altered it does not however address improvement in detection of DUID. The current option does not 
permit MIT or mandatory drug testing after a collision.  Only evidence of impaired driving is permitted 
and only when the driver is very obviously impaired is the Garda able to form the opinion that the driver 
is impaired. The impairment based approach does not address the increased collision involvement risk 
of drug using drivers when driver impairment is not readily observable. Moreover the impairment 
approach does not provide a high level of deterrence from using drugs and driving as the enforcement is 
not generally visible [60]. The current levels of detection do not match levels of prosecutions and the 
level of successful prosecutions remains low. 
8.6.2: Option 2 - Current Position (Option 1) in Combination with Road Traffic Impairment Testing 
(RTIT) 
This option has been considered and is in the process of being introduced and is a clear improvement on 
the current position. The introduction of RTIT would assist the Garda in identifying impairment by the 
driver and improve the evidence of impairment required by the Courts.  However while this position 
would assist with identifying impairment it would still not provide fully for mandatory drug testing or 
mandatory testing following a collision. Even with consideration of the time required for conducting the 
roadside testing and the additional recording of evidence this option is very workable and necessary. 
8.6.3: Option 3 - Chemical Testing at the Roadside Alone 
The introduction of oral fluid testing alone at the roadside would be a relatively quick method to detect 
presence of a drug or drugs using a non-invasive test.  It could be used for mandatory drug testing and 
mandatory drug testing after collisions.  However its main drawback is that it would not include all 
impairing drugs.  It is not inexpensive. There are operational issues which can be addressed in training.  
The level of sensitivity and specificity are not as high for certain drugs and still requires improvement.  
The tests can lead to false positives and false negatives.  This option on its own is an improvement but 
falls short of a comprehensive solution.  
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8.6.4: Option 4 - Chemical Testing at the Roadside and RTIT 
This option has the advantages of option 2 and option 3 combined and provides the Gardaí with 
additional tests if the drug is not detected by oral fluid device and impaired driving due to drugs is still 
considered.  It should increase the levels of detections.  It would provide for mandatory intoxicated 
screening similar to the MAT.  At an MIT checkpoint, the Garda would have the opportunity to make 
initial observation; followed by mandatory alcohol testing; followed by preliminary drug screening with 
a suitable device for the number of specified and appropriate drugs if the alcohol breathalyser was 
negative; and then proceeding to formal road traffic impairment testing if the drug screening also 
proved negative but in the presence of apparent observed impairment. Detection on the basis of 
observed impairment driving but not at an MIT checkpoint would follow a similar structured assessment 
and detection pathway. The main disadvantage of this process is the additional time that would be 
required at the roadside and the cost of testing.  The Garda should have the choice whether to use a 
device of not. If alcohol over the limit is detected then it may not be necessary to check for drugs, 
however the level of drugs and alcohol in combination whilst driving is also an issue that needs to be 
addressed. With this option the Garda is not restricted to under the limit alcohol drivers being tested for 
the presence of a drug or drugs. It is not expected that each motorist will be checked with a drug test at 
a MIT checkpoint, it should depend on the Garda’s initial observation and the use (and cost) of the drug 
test should be exercised with due diligence. 
 
8.7: Recommendations 
The considered recommendations of the authors of this report are that roadside drug intoxicant testing 
should progress in sequenced steps as follows:  
Step 1: Continue the current position with the addition of RTIT being made operational as soon as 
practicable (Option 2); 
Step 2: The introduction of roadside chemical testing as soon as practicable (Option 4).  
The legislative framework modelled on the successful mandatory alcohol screening methodology should 
be introduced.  This legislation should also allow for the zero tolerance approach for illicit drugs and 
drugs taken illicitly and the impairment plus presence for drugs which are authorised medicinal products 
taken in accordance with prescription or on healthcare (including pharmacist) advice.  
Road traffic impairment testing will always be a required part of the strategy in assessing DUID at the 
roadside even when in the future roadside testing devices for certain classes of drugs are available, and 
their use implemented.   This will include the fact that roadside screening devices will always technically 
and scientifically be behind the emergence of new classes of drugs or the modifications of existing drugs 
of which the “head shop drugs” were the most recent widely acknowledged example.    
The MBRS thus recommends the implementation of these options 2 and 4 as the strategy which will 
increase the detection, enforcement and deterrence of drugs driving in Ireland. 
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Chapter 9: Implementation of the Roadside Drug Testing 
Recommendation 
9.1: Introduction 
In order to progress Option 4, it is assumed that Option 2 (current situation with implementation of 
RTIT) will have been successfully commenced and that this chapter is addressing the introduction of oral 
fluid chemical testing devices under Option 4.  Several steps will have to be taken and an agreed 
timeframe set out as between the DTTAS, MBRS and GNTB to commence the process.  Resources and 
cost areas associated with the introduction are also identified where possible. 
The following steps have been identified at this stage and are outlined below. 
9.2: Formation of a Working Group 
 A working group comprising the three bodies concerned (MBRS, DTTAS and an Garda Síochána) would 
need to be set up immediately after the DTTAS requests the introduction of oral fluid testing at the 
roadside.  The working group will need to address all the issues required to commence the process 
which include scientific, operational, legislative, resources and costs. 
9.3: Development of a Knowledge Base 
The working group will be charged with setting out the requirements of the devices. The MBRS scientists 
have a good understanding of the analytical technology employed in the devices but the working group 
would require more knowledge in the assessment and the procurement and operational set up 
processes.  As can be seen from Chapter 7, these processes have been conducted by other jurisdictions 
and in the case of France have been successfully conducted twice in the past.  Inspection and active 
assessments of existing programmes in one or two jurisdictions should be considered as this would 
assist the working group in obtaining an overall picture of the legal, operational and scientific 
requirements for the introduction of this new roadside drug testing.  The costs of these inspections 
could be kept to a minimum if jurisdictions identified were nearby. 
Another consideration is the possibility of a field trial being conducted as part of the process.  A field 
trial was conducted before the introduction of evidential breath testing but the numbers gathered in the 
original 6 month time frame was too small and the trial had to be extended for a further 6 months and 
the final response from drivers was considered very low.  The advantages of a field trial would be that 
both GardaÍ and Scientists would gain experience with the devices, the MBRS would gain knowledge of 
the level of support from the manufacturers in troubleshooting and the experience gained would 
contribute greatly to the setup process.  A field trial would also assist the DTTAS in drawing up 
legislation.   There were legal restrictions with the EBT field trial and this could also be a possibility here. 
There would also be time, resources and cost considerations with this suggestion and the learning 
outcomes may not justify these outlays. 
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9.4: Establish Specifications 
As already outlined in there are no international or EU standards set out for these devices unlike the 
breath alcohol testing devices and it will be necessary for the MBRS to set out its own specifications for 
device approval. It will take into consideration the advices from the working group and also the 
experiences of other jurisdictions. The specifications will be used for the procurement processes used by 
the MBRS. 
The working group will have to decide on what type of device is best suited to Garda operators with 
special regard for proofs required.  As can be seen from chapter 7 (Practices in Other Countries) each 
country has adopted its own approach and with advances in technology there are both stand-alone 
single use cassettes and electronic devices available.  Electronic devices can issue printed reports.  Each 
type can be considered either before setting out the specifications for procurement or as part of the 
evaluation process during procurement.  In the case of electronic devices the specifications will be 
considerably more detailed and will include specifications in  relation to power supply, radiofrequency, 
temperature and climate to name but a few.  If no restriction on type is to be considered before 
procurement then the electronic specifications will need to be included and reflected in the timeframe 
for the commencement of the project. 
The working group will also need to consider the number of drugs to be targeted by the device and 
again as outlined in Chapter 7 different countries and different jurisdictions have taken different 
approaches to this decision. The decision can be for legal, financial or operational reasons and all will 
have to be given careful consideration in reference to the situation here in Ireland. 
9.5: Amend the Road Traffic Act 
The working group will also need to identify legislative changes required and agree the timeframe for 
these changes to be in place. The working group members can also consult relevant bodies in relation to 
legislative issues that arise. Roadside drug testing will demand considerably more time at the roadside 
and legislation will need to permit detention of the driver, taking of oral fluid specimen, consideration as 
to the order of the tests and the reporting of the tests,  It will be very important that legislation and 
protocols will not be too restrictive as the number and types of drugs will be subject to change (see 
chapter 2)  and cut-off levels should not be included as they can depend on the analytical capabilities of 
devices currently on the market and into the future.  The need for documentation should be given 
careful consideration and also the information to be given to the laboratory as a result of the roadside 
tests.  This part of the process can be operating   in tandem with the other steps identified.    
9.6: Establish Oral Fluid Device Testing Laboratory 
When the working party has agreed the specifications for the devices and estimated the quantities that 
will be required, the MBRS and the Gardaí will also have to agree a testing protocol for assessment of 
the devices and the MBRS will also have to set up a device testing laboratory. This laboratory will be 
used for the initial testing of the devices for approval by the MBRS but also for the ongoing testing of 
devices supplied to Gardaí on a regular basis into the future.    It will be necessary to source relevant 
standards in oral fluids and develop tests to detect targeted drugs if not already being carried out in 
blood or urine specimens in the laboratory.  It may also be necessary to outsource some of this testing if 
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narrow time constraints are placed on the project.  In the case of an electronic device being considered, 
the testing protocols will need to include additional laboratory tests for evaluation of specifications in a 
similar way to electronic breath alcohol testing devices including; radiofrequency, power supply and 
temperature.  It will be necessary to validate the test method for whatever device is selected and the 
MBRS will seek accreditation for the test procedure.  Accreditation will be sought for the testing of the 
devices before issue.  In the case of electronic devices there will be a need to set up an inspection and 
calibration checking programme similar to the current regime for the roadside alcohol testing devices.  
The latter issues will not affect the timeframe for the introduction of the devices. The MBRS has the 
infrastructure and scientific knowledge to set up the laboratory but will require additional scientific 
resources for this task at the initial stage of the process and in the case of electronic devices for testing 
into the future. If the MBRS is required to rely on current resource levels, the timeframe for 
implementation will of necessity be extended. 
9.7: Procurement Process 
The tender process will be conducted according to EU procurement requirements and the appropriate 
timeframes will have to be adhered to. However additional time may be required to assess the devices 
depending on the agreed testing protocol.  The testing of electronic devices as outlined previously will 
also need time consideration in the procurement timeframe.  
9.8: Approval, Supply and Testing of Devices by the MBRS 
Following the successful completion of the procurement process, the MBRS will order the agreed 
required amount of devices. The lead-time for the initial order may depend on whether the order 
requires modifications unique to the Irish jurisdiction or not. If the vendor has a suitable off the shelf 
product available there should be minimal lead-times and the quantities of devices required should be 
the only consideration at this stage.  However if the order is a bespoke order then additional time may 
need to be factored into the timeframe.  The devices must be approved by the Board of the MBRS 
before use. They will also be tested by the MBRS before issue to the Gardaí.  This testing would need to 
be included in the timeframe.  Future orders would then be planned in a similar manner by the MBRS in 
consultation with the GNTB on an annual basis. 
9.9: Training  
These devices will be used by any Garda operator as a preliminary drug screen and should not require 
extensive training. The operator of the device will follow the instructions of the manufacturer and the 
legal protocol as proscribed.  The manufacturer or their agent and the Bureau will train the Garda 
trainers. The Garda trainers will then be in position to train the Garda operators. This is similar to the 
training of Gardaí in the use of the roadside breath test devices.  Training will also be part of the overall 
timeframe for the introduction of the devices.  Costs for training the Garda operators will be a matter 
for the Garda authorities. The cost of the training courses of the trainers will be borne by the Bureau. 
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9.10: Timeframe for Implementation of Roadside Drug Testing 
Recommendation 
It is estimated at this stage that the process set out above would take at least two years.  By 
comparison, this is similar to the timeframe as set out for the United Kingdom in the North Report 
(Recommendation 11 of that report) [11].  However this timeframe is a preliminary estimate which 
could only be finalised following the deliberations of the working group as it depends on a number of 
critical decisions of the working group.  
The legislative process timescale is separate and distinct.  
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Glossary of Terms and Acronyms  
 
Accuracy: Accuracy is a mathematical combination of specificity and 
sensitivity and is the measure of the tests ability to return the 
correct result whether it is positive or negative. 
Antibodies: Proteins produced by animals which have highly specific binding 
properties to specific chemicals. 
Buffer: Fluid which when oral fluid is added to it maintains its original 
pH. 
CEN: European committee for standardisation. 
Centrifugation: A method of separating components in a mixture using 
centrifugal force. 
CIT: Compulsory Impairment Test. 
CLT: Confirmatory Laboratory Test. 
CNS: Central Nervous System. 
Cut –off: A concentration level at or above which a result is deemed 
positive and below which it is deemed negative. 
Diluent:    Fluid used to dilute.  
DIT: Dublin Institute of Technology. 
Drug Recognition Expert: Suitably trained individual who conducts a series of tests, 
including impairment and physiological tests, in order to 
determine driver impairment and also the likely drug class 
causing such impairment. Drug Recognition Experts usually 
carry out their tests in a police station.     
Drug:  In the context of this report a drug is any chemical substance 
other than alcohol which can impair driving. 
DRUID:     Driving Under the Influence of Drugs. 
Dry Mouth: A condition which can be pathological or drug induced, which 
results in a reduction in saliva production. 
DTTAS: Department of Transport, Tourism and Sport. 
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DUID Driving under the influence of a drug(s). 
DVLA:     Driver Vehicle Licensing Authority, U.K. 
EMCDDA:    European Monitoring Centre for Drugs and Drug Addiction. 
ESTHER: Evaluation of oral fluid Screening devices by TISPOL to 
Harmonise  European  Police Requirements. 
Field Impairment Test: Impairment test carried out at or close to the location where 
impairment is suspected (See impairment test below). 
GC-MS:     Gas Chromatography-Mass Spectrometry. 
GC-MS-MS:    Gas Chromatography-Tandem Mass Spectrometry. 
GNTB: Garda National Traffic Bureau.  
HRB:  Health Research Board. 
IMMORTAL: Impaired Motorists, Method Of Roadside Testing and 
Assessment for Licensing. 
Immunoassay: A test that utilises purified antibodies to determine the 
presence of a drug. 
Immuno-chromatographic device:  A drug testing device which incorporates a simple sample 
preparations step and an immunoassay.  
Impairment test: A test or series of tests which are used to assess a person’s 
psychomotor and cognitive skills. 
Impairment Threshold Refers to level at which a person is deemed to be impaired.  
Intoxicant:  Alcohol and drugs and any combination of drugs or of drugs and 
alcohol. 
Last Month Prevalence: Refers to the proportion of a sample of a population who have 
reported using a drug in the last 30 days. 
LC-MS:     Liquid Chromatography-Mass Spectrometry. 
LC-MS-MS:    Liquid Chromatography-Tandem Mass Spectrometry. 
Lifetime Prevalence: Refers to the proportion of a sample of a population who have 
reported ever having used a drug. 
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Limit of detection: Lowest detectable level permitted by the detection system 
used. 
Limit of quantitation: Lowest detectable level that can be quantitated accurately by 
the detection system used . 
Lipophilic: Term used to describe chemical entity which dissolves well is 
lipid based system rather than aqueous based systems. 
MAT:     Mandatory Alcohol Test. 
Matrix Effects: Factors which can affect the detection of drug in a particular 
matrix such as oral fluid or blood.   
MBRS:     Medical Bureau of Road Safety. 
Medicinal Product: Drug or Drug preparation authorised for human use. 
mg/100ml: Milligram per 100mL, unit of measurement used to describe the 
concentration of alcohol in blood or urine. 1mg/100ml is 
equivalent to 1 part per 100,000. 
MIT:     Mandatory Intoxicant Test. 
NACD: National Advisory Committee on Drugs. 
NDRDI: National Drug Related Deaths Index. 
ng/ml: Nanogram per millilitre, unit of concentration commonly used 
to express the concentration of drug in a particular biological 
specimen. 1ng/ml is equivalent to 1 part per billion (ppb).  
NHTSA:     National Highway Traffic Safety Administration, U.S.A. 
OIML: International Organisation for Legal Metrology. 
On-Site Oral Fluid Test: A test that can be conducted at the road side. 
Oral Fluid Collection Device:  A device used to collect oral fluid for testing.    
Oral fluid: Fluid produced by glands in the mouth which contains a mixture 
of saliva, proteins and other materials. 
Per se: Refers to legislation which specifies concentration levels for a 
drug and/or alcohol. A per se level is the maximum allowable 
concentrations above which an offence is committed. 
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pg/ml  Picogram per millilitre, unit of concentration used to express 
the concentration of drug in a particular biological specimen. 
1ng/ml is equivalent to 1 part per trillion (ppt). 
pH Measure of the acidity/alkalinity of a material. The pH scale is 0-
14.  pH 7 is neutral, <7 is acidic,  >7 is alkaline.  
Pharmacodynamics:   The effect the drug has on the body. 
Pharmacokinetics:   How the body processes a drug e.g. Transport and Metabolism. 
PHIRB: Public Health Information and Research Branch. 
pKa: Dissociation constant of a molecule.  
RCPI: Royal College of Physicians Ireland. 
RTIT: Road Traffic Impairment Test, the name given to the 
impairment tests to be carried out in the Republic of Ireland. 
ROSITA:    Roadside Testing Assessment. 
RSA:  Road Safety Authority. 
RTA:     Road Traffic Act. 
RTC:     Road Traffic Collision. 
Saliva:  Fluid produced by parotid, sub-maxillary and sublingual glands 
in the mouth. 
Sensitivity: The ability of a particular test to determine a positive test result 
when it should. This is often expressed as a percentage 100% is 
completely sensitive, 0% is completely insensitive. 
Specificity: The ability of particular test to correctly determine a negative 
result when it should. This is often expressed as a percentage 
100% is completely specific, 0% is completely unspecific. 
THC: Δ9-Tetrahydrocannabinol. 
Zero Tolerance:     Offence committed if any detectable level of the drug is found. 
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Appendix 1 
Results of MBRS DUID Survey March 2012 
The Bureau contacted colleagues in 13 different countries and presented a DUID questionnaire to them. 
There were 8 completed questionnaires. Another 2 colleagues started but did not complete the 
questionnaire, the first person did not consider that the questionnaire applied to their country and the 
second was not in position to provide cut-off information. Colleagues from 3 countries did not respond.  
The countries that replied to the questionnaire were as follows: France, Switzerland, Canada, Germany, 
Norway, Belgium, USA and Denmark, both Sweden and Finland replied by Email. 
The following information was obtained from the 8 questionnaires: 
Q1.  When was legislation introduced in your jurisdiction? 
The date of implementation varied from the 1950s for the USA to 2012 for Norway who introduced a 
legal limit for 20 specified drugs this year. 
Q2.  When can police stop the driver? 
 7 indicated on suspicion of DUID 
 3 indicated at random 
 3 indicated mandatory after a collision  
 And only one indicated that a traffic offender can be stopped. 
Q3.  What type of test is permitted? 
 6 indicated roadside assessment of driver 
 3 indicated legislation based specific performance impairment tests  
 4  indicated oral fluid tests 
 1 indicated oral fluid available in law but not in use yet. 
 1 indicated performance test used only when prescribed medicine is used 
 Only 1 indicated that a urine test is permitted 
Q4.  What is the average completion time for the process at the roadside?  
 3 indicated less than 10 minutes (with one person qualifying their response) 
 3 indicated 10-20 minutes 
 1 indicated 20-30 minutes 
 2 indicated greater than 40 minutes (with one person qualifying their response)  
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Q5.  What evidential standard is required? 
 6 indicated evidence of impairment is required 
 6 indicated per se limits for some specified drugs 
 2 indicated zero tolerance for illegal drugs 
 1 indicated per se limits for medicinal drugs without prescription 
Q6.  What drugs are specified in legislation? 
 5 indicated illegal drugs only 
 3 indicated all impairing drugs 
 Marijuana is exempt from the illegal drugs list in some States in the USA. 
 Norway indicated that 20 drugs are now specified in legislation since February 2012 
Q7. Please describe the roadside testing device used in your jurisdiction? 
 4 indicated none used 
 3 indicated Drugwipe5 used 
 1 indicated that different devices are used by different police forces  
Q8. In the case of oral fluid what are the cut-off concentrations (ng/ml) for the following drugs? The 
number of respondents reporting specific cut-offs are in parentheses. 
 Amphetamine  50ng/ml (2), 100ng/ml (1),  MDMA 50ng/ml (1),  MDEA 100ng/ml  
 Methamphetamine 50ng/ml (3) 
 Opiates 10ng/ml (2), Morphine 20ng/ml (1) 
 THC 15ng/ml (1) , 25ng/ml (1), 30ng/ml (1) 
 Cocaine 10ng/ml (1), 20ng/ml (1), 50ng/ml (1), Benzoylecgonine 100ng/ml (1) 
Q9. What specimen type(s) is used for confirmation? 
 1 Oral Fluid & Blood 
 1 Oral Fluid & Urine 
 1 Blood & Urine 
 4 Blood 
 1 Urine 
84 
Q10. What is the confirmation cut-off concentrations (ng/ml) for the following drugs? 
In all 2 countries gave no indication, 1 country indicated that it varied by State and laboratory. The 
results of the remaining 5 countries are as follows and are blood cut-off levels: 
 Amphetamines range;  15-50ng/ml and 0.03mg/kg 
 Methamphetamine  range;  15-50ng/ml and 0.03mg/kg 
 Benzodiazepines  
o 2 did not indicate that benzodiazepines were applicable 
o 2 indicated that there are different cut-offs for the different benzodiazepines  
o 1 indicated that cut-off was limit of quantitation of the laboratory 
 Opiates 
o Morphine  range 9-15ng/ml and 0.015mg/kg 
o Opiates range 10-20ng/ml 
o Others indicated limit of quantitation of laboratory as the cut-off 
 Cannabis (THC) 
o Range 0.6-1.5ng/ml and 0.0015mg/kg 
o Cannabis (THC acid) 
 4 indicated ‘not applicable’ 
o 1 indicated limit of quantitation of laboratory as the cut-off 
 Cocaine range; 15 -50ng/ml and 0.015mg/kg 
o 1 indicated that metabolites cut-off was limit of quantitation of the laboratory  
 Methadone 
o 1 country had a cut-off value of 19ng/ml  
o 1 country had a cut-off value of 0.075mg/kg  
o 1 country indicated the limit of quantitation of the  laboratory as the cut-off 
o Other countries did not indicate whether methadone is tested for or not 
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o One country indicated its cut-off levels for Oral Fluid in ng/ml 
 Amphetamine 25ng/ml 
 Methamphetamine 25ng/ml 
 Opiates 5ng/ml 
 THC 10ng/ml 
 Cocaine 10ng/ml 
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